Compared B-Premise
only I-Premise
with I-Premise
patients I-Premise
with I-Premise
SD I-Premise
( I-Premise
6m I-Premise
) I-Premise
, I-Premise
responders I-Premise
showed I-Premise
no I-Premise
significant I-Premise
difference I-Premise
in I-Premise
baseline I-Premise
QL I-Premise
and I-Premise
time I-Premise
to I-Premise
treatment I-Premise
failure I-Premise
( I-Premise
328.5 I-Premise
v I-Premise
340 I-Premise
days I-Premise
) I-Premise
. I-Premise

Adjustments O
were O
made O
for O
the O
baseline O
score O
. O

The B-Premise
incremental I-Premise
cost-effectiveness I-Premise
ratio I-Premise
was I-Premise
19,39£ I-Premise
per I-Premise
quality-adjusted I-Premise
life I-Premise
year I-Premise
. I-Premise

At O
disease O
progression O
, O
temozolomide O
salvage O
treatment O
was O
given O
to O
161 O
of O
282 O
patients O
( O
57 O
% O
) O
in O
the O
radiotherapy O
alone O
arm O
, O
and O
to O
62 O
of O
277 O
patients O
( O
22 O
% O
) O
in O
the O
temozolomide O
+ O
radiotherapy O
arm O
. O

ORR O
was O
20 O
% O
with O
a O
7.2-month O
median O
response O
duration O
. O

Intrusive B-Premise
thoughts I-Premise
also I-Premise
influenced I-Premise
the I-Premise
trajectory I-Premise
of I-Premise
pain I-Premise
, I-Premise
depressive I-Premise
symptoms I-Premise
, I-Premise
negative I-Premise
affect I-Premise
, I-Premise
and I-Premise
physical I-Premise
functioning I-Premise
over I-Premise
time I-Premise
";" I-Premise
women B-Premise
with I-Premise
higher I-Premise
intrusions I-Premise
at I-Premise
baseline I-Premise
started I-Premise
worse I-Premise
and I-Premise
improved I-Premise
over I-Premise
time I-Premise
, I-Premise
whereas I-Premise
those I-Premise
with I-Premise
lower I-Premise
intrusions I-Premise
remained I-Premise
at I-Premise
a I-Premise
constant I-Premise
, I-Premise
lower I-Premise
level I-Premise
over I-Premise
time I-Premise
. I-Premise

Grade B-Premise
4 I-Premise
neutropenia I-Premise
( I-Premise
27 I-Premise
% I-Premise
v I-Premise
19 I-Premise
% I-Premise
) I-Premise
and I-Premise
infusion I-Premise
site I-Premise
pain I-Premise
( I-Premise
10 I-Premise
% I-Premise
v I-Premise
0.5 I-Premise
% I-Premise
) I-Premise
were I-Premise
reported I-Premise
more I-Premise
frequently I-Premise
in I-Premise
the I-Premise
ASA404 I-Premise
arm I-Premise
. I-Premise

Future B-Claim
work I-Claim
is I-Claim
needed I-Claim
to I-Claim
improve I-Claim
the I-Claim
design I-Claim
and I-Claim
the I-Claim
planning I-Claim
of I-Claim
these I-Claim
interventions I-Claim
to I-Claim
improve I-Claim
program I-Claim
adherence I-Claim
. I-Claim

The B-Premise
use I-Premise
of I-Premise
prophylactic I-Premise
tamsulosin I-Premise
resulted I-Premise
in I-Premise
a I-Premise
statistically I-Premise
lower I-Premise
dysuria I-Premise
severity I-Premise
score I-Premise
( I-Premise
difference I-Premise
of I-Premise
2.7 I-Premise
vs I-Premise
4.2 I-Premise
, I-Premise
P I-Premise
< I-Premise
0.005 I-Premise
) I-Premise
at I-Premise
1 I-Premise
month I-Premise
, I-Premise
with I-Premise
no I-Premise
discernible I-Premise
differences I-Premise
at I-Premise
3 I-Premise
, I-Premise
6 I-Premise
, I-Premise
12 I-Premise
and I-Premise
18 I-Premise
months I-Premise
. I-Premise

A O
total O
of O
402 O
eligible O
patients O
were O
registered O
to O
step O
1 O
, O
and O
223 O
eligible O
patients O
were O
registered O
to O
step O
2 O
( O
observation O
, O
n O
= O
111 O
";" O
topotecan O
, O
n O
= O
112 O
) O
. O

However O
, O
it O
is O
rarely O
implemented O
given O
its O
limited O
availability O
. O

However O
, O
intervention B-Premise
patients I-Premise
had I-Premise
significantly I-Premise
better I-Premise
scores I-Premise
at I-Premise
months I-Premise
3 I-Premise
and I-Premise
6 I-Premise
( I-Premise
median I-Premise
3-month I-Premise
intervention I-Premise
score I-Premise
, I-Premise
7 I-Premise
[ I-Premise
range I-Premise
, I-Premise
5-7 I-Premise
] I-Premise
, I-Premise
vs I-Premise
median I-Premise
control I-Premise
score I-Premise
, I-Premise
5 I-Premise
[ I-Premise
range I-Premise
, I-Premise
3-7 I-Premise
] I-Premise
[ I-Premise
P I-Premise
= I-Premise
.03 I-Premise
] I-Premise
";" I-Premise
median I-Premise
6-month I-Premise
intervention I-Premise
score I-Premise
, I-Premise
7 I-Premise
[ I-Premise
range I-Premise
, I-Premise
6-7 I-Premise
] I-Premise
, I-Premise
vs I-Premise
median I-Premise
control I-Premise
score I-Premise
, I-Premise
6 I-Premise
[ I-Premise
range I-Premise
, I-Premise
3-7 I-Premise
] I-Premise
[ I-Premise
P I-Premise
= I-Premise
.009 I-Premise
] I-Premise
) I-Premise
. I-Premise

The B-Claim
results I-Claim
of I-Claim
this I-Claim
brief I-Claim
pilot I-Claim
counseling I-Claim
intervention I-Claim
demonstrated I-Claim
significant I-Claim
gains I-Claim
in I-Claim
sexual I-Claim
function I-Claim
and I-Claim
satisfaction I-Claim
and I-Claim
increased I-Claim
utilization I-Claim
of I-Claim
treatments I-Claim
for I-Claim
ED I-Claim
. I-Claim

No B-Premise
differences I-Premise
in I-Premise
patients I-Premise
' I-Premise
preference I-Premise
for I-Premise
the I-Premise
two I-Premise
treatment I-Premise
periods I-Premise
were I-Premise
found I-Premise
. I-Premise

Out O
patient O
group O
, O
Department O
of O
Physical O
Medicine O
and O
Rehabilitation O
and O
Medical O
Oncology O
Department O
, O
University O
Hospital O
. O

After B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
23 I-Premise
months I-Premise
, I-Premise
both I-Premise
groups I-Premise
had I-Premise
similar I-Premise
progression-free I-Premise
survival I-Premise
( I-Premise
medians I-Premise
of I-Premise
15.0 I-Premise
months I-Premise
for I-Premise
docetaxel-carboplatin I-Premise
and I-Premise
14.8 I-Premise
months I-Premise
for I-Premise
paclitaxel-carboplatin I-Premise
";" I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
docetaxel-paclitaxel I-Premise
= I-Premise
0.97 I-Premise
, I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
= I-Premise
0.83 I-Premise
to I-Premise
1.13 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.707 I-Premise
) I-Premise
, I-Premise
overall I-Premise
survival I-Premise
rates I-Premise
at I-Premise
2 I-Premise
years I-Premise
( I-Premise
64.2 I-Premise
% I-Premise
and I-Premise
68.9 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
HR I-Premise
= I-Premise
1.13 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0.92 I-Premise
to I-Premise
1.39 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.238 I-Premise
) I-Premise
, I-Premise
and I-Premise
objective I-Premise
tumor I-Premise
( I-Premise
58.7 I-Premise
% I-Premise
and I-Premise
59.5 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
difference I-Premise
between I-Premise
docetaxel I-Premise
and I-Premise
paclitaxel I-Premise
= I-Premise
-0.8 I-Premise
% I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
-8.6 I-Premise
% I-Premise
to I-Premise
7.1 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
.868 I-Premise
) I-Premise
and I-Premise
CA-125 I-Premise
( I-Premise
75.8 I-Premise
% I-Premise
and I-Premise
76.8 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
difference I-Premise
docetaxel-paclitaxel I-Premise
= I-Premise
-1.0 I-Premise
% I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
-7.2 I-Premise
% I-Premise
to I-Premise
5.1 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
.794 I-Premise
) I-Premise
response I-Premise
rates I-Premise
. I-Premise

Notably O
, O
ablation O
preparation O
using O
withdrawal O
of O
LT3 O
for O
2 O
weeks O
did O
not O
prevent O
development O
of O
profound O
hypothyroidism O
, O
as O
also O
occurred O
when O
LT4 O
alone O
was O
withdrawn O
for O
4 O
weeks O
. O

Local O
symptoms O
were O
scored O
on O
a O
physician-assessed O
, O
five-point O
categorical O
scale O
and O
summed O
to O
produce O
a O
total O
symptom O
score O
( O
TSS O
) O
. O

Both B-Premise
EBRT I-Premise
and I-Premise
cryoablation I-Premise
participants I-Premise
reported I-Premise
decreases I-Premise
in I-Premise
sexual I-Premise
function I-Premise
at I-Premise
3 I-Premise
months I-Premise
with I-Premise
the I-Premise
cryoablation I-Premise
patients I-Premise
reporting I-Premise
poorer I-Premise
functioning I-Premise
( I-Premise
mean I-Premise
cryoablation=7.2 I-Premise
: I-Premise
mean I-Premise
EBRT=32.9 I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

At B-Premise
the I-Premise
six I-Premise
month I-Premise
follow-up I-Premise
, I-Premise
most I-Premise
of I-Premise
these I-Premise
effects I-Premise
were I-Premise
maintained I-Premise
and I-Premise
an I-Premise
intervention I-Premise
effect I-Premise
for I-Premise
breast I-Premise
cancer I-Premise
specific I-Premise
quality I-Premise
of I-Premise
life I-Premise
emerged I-Premise
. I-Premise

Results O
for O
functional O
outcome O
and O
quality O
of O
life O
are O
rarely O
reported O
beyond O
10 O
years O
and O
are O
lacking O
from O
randomised O
settings O
. O

Health-Related O
Quality O
of O
Life O
[ O
RAND-36 O
and O
Rotterdam O
Symptom O
Check O
List O
( O
RSCL O
) O
] O
, O
exercise O
capacity O
( O
symptom O
limited O
bicycle O
ergometry O
) O
, O
muscle O
force O
( O
hand-held O
dynamometry O
) O
, O
and O
patient O
preferences O
. O

No B-Premise
difference I-Premise
in I-Premise
median I-Premise
overall I-Premise
survival I-Premise
was I-Premise
detected I-Premise
( I-Premise
57 I-Premise
months I-Premise
for I-Premise
fludarabine I-Premise
v I-Premise
44 I-Premise
months I-Premise
for I-Premise
CVP I-Premise
";" I-Premise
P I-Premise
=.95 I-Premise
) I-Premise
. I-Premise

Minimum O
followup O
was O
12 O
months O
. O

Twenty O
patients O
completed O
the O
study O
. O

Patients O
and O
clinical O
sites O
were O
informed O
of O
allocation O
to O
early O
treatment O
, O
and O
treatment O
was O
started O
as O
soon O
as O
possible O
within O
28 O
days O
of O
the O
increased O
CA125 O
measurement O
. O

A O
total O
of O
118 O
patients O
( O
59 O
per O
arm O
) O
were O
randomly O
assigned O
to O
receive O
IFN O
at O
a O
dose O
of O
0.5 O
million O
units O
( O
MU O
) O
given O
subcutaneously O
twice O
daily O
( O
IFN1 O
) O
or O
IFN O
at O
a O
dose O
of O
5 O
MU O
given O
subcutaneously O
daily O
( O
IFN5 O
) O
. O

HRQOL B-Claim
evaluated I-Claim
3.2 I-Claim
to I-Claim
6.5 I-Claim
years I-Claim
after I-Claim
treatment I-Claim
showed I-Claim
an I-Claim
advantage I-Claim
for I-Claim
BT I-Claim
in I-Claim
urinary I-Claim
and I-Claim
sexual I-Claim
domains I-Claim
and I-Claim
in I-Claim
patient I-Claim
satisfaction I-Claim
. I-Claim

AET B-Claim
did I-Claim
not I-Claim
significantly I-Claim
improve I-Claim
sleep I-Claim
quality I-Claim
in I-Claim
this I-Claim
heterogeneous I-Claim
sample I-Claim
of I-Claim
patients I-Claim
with I-Claim
lymphoma I-Claim
";" I-Claim
however B-Claim
, I-Claim
clinically I-Claim
identifiable I-Claim
subgroups I-Claim
appeared I-Claim
to I-Claim
benefit I-Claim
. I-Claim

This O
randomized O
, O
multicenter O
, O
phase O
III O
study O
compared O
doxorubicin O
and O
docetaxel O
( O
AT O
) O
with O
doxorubicin O
and O
cyclophosphamide O
( O
AC O
) O
as O
first-line O
chemotherapy O
( O
CT O
) O
in O
metastatic O
breast O
cancer O
( O
MBC O
) O
. O

Side O
effects O
of O
appetite O
increase O
and O
weight O
gain O
at O
higher O
doses O
were O
predicted O
to O
have O
a O
negative O
effect O
on O
quality O
of O
life O
. O

Vinorelbine B-Claim
improves I-Claim
survival I-Claim
of I-Claim
elderly I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
NSCLC I-Claim
and I-Claim
possibly I-Claim
improves I-Claim
overall I-Claim
QoL I-Claim
. I-Claim

Patients B-Premise
with I-Premise
an I-Premise
objective I-Premise
tumor I-Premise
response I-Premise
reported I-Premise
better I-Premise
physical I-Premise
well-being I-Premise
( I-Premise
P I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
, I-Premise
mood I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
, I-Premise
functional I-Premise
performance I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
and I-Premise
less I-Premise
effort I-Premise
to I-Premise
cope I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
compared I-Premise
with I-Premise
the I-Premise
non-responders I-Premise
and I-Premise
stable I-Premise
disease I-Premise
patients I-Premise
. I-Premise

In B-Premise
limited I-Premise
disease I-Premise
the I-Premise
estimated I-Premise
percentages I-Premise
of I-Premise
survival I-Premise
at I-Premise
2 I-Premise
years I-Premise
were I-Premise
33 I-Premise
% I-Premise
in I-Premise
the I-Premise
early I-Premise
and I-Premise
24 I-Premise
% I-Premise
in I-Premise
the I-Premise
late I-Premise
alternating I-Premise
chemotherapy I-Premise
arms I-Premise
. I-Premise

A O
multicentre O
pragmatic O
randomised O
controlled O
trial O
( O
RCT O
) O
with O
a O
2×2 O
factorial O
design O
was O
performed O
among O
320 O
breast O
cancer O
patients O
who O
were O
treated O
with O
curative O
intent O
. O

Transthoracic O
and O
transhiatal O
esophagectomy O
are O
two O
common O
procedures O
for O
esophageal O
cancer O
resection O
. O

bolus O
( O
arm O
A O
) O
";" O
TOM O
, O
3 O
mg/m2 O
i.v O
. O

One O
hundred O
twenty-eight O
of O
177 O
eligible O
patients O
of O
a O
randomized O
trial O
( O
Swiss O
Group O
for O
Clinical O
Cancer O
Research O
20/90 O
) O
receiving O
either O
formestane O
( O
250 O
mg O
intramuscularly O
biweekly O
) O
or O
megestrol O
acetate O
( O
160 O
mg O
orally O
daily O
) O
were O
analyzed O
. O

165 O
of O
441 O
patients O
were O
assigned O
to O
dignity O
therapy O
, O
140 O
standard O
palliative O
care O
, O
and O
136 O
client-centred O
care O
. O

There B-Premise
was I-Premise
a I-Premise
significant I-Premise
interaction I-Premise
between I-Premise
gender I-Premise
and I-Premise
KPS I-Premise
using I-Premise
FLIC I-Premise
( I-Premise
P I-Premise
= I-Premise
0.009 I-Premise
) I-Premise
, I-Premise
which I-Premise
also I-Premise
showed I-Premise
a I-Premise
trend I-Premise
toward I-Premise
significance I-Premise
with I-Premise
FACT I-Premise
( I-Premise
P I-Premise
= I-Premise
0.09 I-Premise
) I-Premise
. I-Premise

Secondary O
endpoints O
included O
response O
rate O
( O
RR O
) O
, O
overall O
survival O
( O
OS O
) O
, O
toxicity O
, O
and O
quality O
of O
life O
( O
QOL O
) O
. O

This O
, O
performance O
status O
, O
Hospital O
Anxiety O
and O
Depression O
( O
HAD O
) O
score O
and O
Spitzer O
's O
quality-of-life O
index O
were O
noted O
before O
treatment O
, O
at O
1 O
month O
after O
treatment O
and O
every O
2 O
months O
thereafter O
. O

a O
15-week O
rehabilitation O
program O
including O
individual O
exercise O
, O
sports O
, O
psycho-education O
, O
and O
information O
. O

The B-Claim
study I-Claim
results I-Claim
suggest I-Claim
that I-Claim
K-tape I-Claim
could I-Claim
replace I-Claim
the I-Claim
bandage I-Claim
in I-Claim
DLT I-Claim
, I-Claim
and I-Claim
it I-Claim
could I-Claim
be I-Claim
an I-Claim
alternative I-Claim
choice I-Claim
for I-Claim
the I-Claim
breast-cancer-related I-Claim
lymphedema I-Claim
patient I-Claim
with I-Claim
poor I-Claim
short-stretch I-Claim
bandage I-Claim
compliance I-Claim
after I-Claim
1-month I-Claim
intervention I-Claim
. I-Claim

Scores B-Premise
on I-Premise
a I-Premise
scale I-Premise
assessing I-Premise
daily I-Premise
functioning I-Premise
and I-Premise
enjoyment I-Premise
( I-Premise
Q-LES-Q I-Premise
) I-Premise
improved I-Premise
from I-Premise
year I-Premise
7 I-Premise
to I-Premise
year I-Premise
9 I-Premise
. I-Premise

In O
a O
prospective O
, O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
, O
407 O
melanoma O
patients O
in O
stage O
IIA O
( O
301 O
patients O
) O
and O
IIB O
( O
106 O
patients O
) O
were O
randomly O
assigned O
to O
either O
IFNalpha O
and O
isotretinoin O
( O
isotretinoin O
group O
";" O
206 O
patients O
) O
or O
IFNalpha O
and O
placebo O
( O
placebo O
group O
";" O
201 O
patients O
) O
after O
excision O
of O
the O
primary O
tumor O
. O

A B-Premise
significant I-Premise
improvement I-Premise
in I-Premise
symptoms I-Premise
after I-Premise
treatment I-Premise
was I-Premise
found I-Premise
on I-Premise
day I-Premise
5 I-Premise
( I-Premise
p I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
and I-Premise
on I-Premise
day I-Premise
10 I-Premise
( I-Premise
p I-Premise
= I-Premise
0.0002 I-Premise
) I-Premise
. I-Premise

ALT B-Premise
had I-Premise
a I-Premise
positive I-Premise
, I-Premise
statistically I-Premise
and I-Premise
clinically I-Premise
significant I-Premise
immediate I-Premise
effect I-Premise
on I-Premise
limb I-Premise
volume I-Premise
but B-Premise
no I-Premise
long-term I-Premise
effect I-Premise
was I-Premise
noted I-Premise
. I-Premise

A O
total O
of O
419 O
women O
were O
randomized O
to O
one O
of O
four O
treatments O
: O
once-daily O
1 O
mg O
E2V/2.5 O
mg O
MPA O
( O
1 O
+ O
2.5 O
group O
) O
";" O
1 O
mg O
E2V/5 O
mg O
MPA O
daily O
( O
1 O
+ O
5 O
group O
) O
";" O
2 O
mg O
E2V/2.5 O
mg O
MPA O
daily O
( O
2 O
+ O
2.5 O
group O
) O
";" O
2 O
mg O
E2V/5 O
mg O
MPA O
daily O
( O
2 O
+ O
5 O
group O
) O
( O
Indivina O
, O
Orion O
Pharma O
) O
. O

The O
final O
sample O
consisted O
of O
235 O
couples O
: O
123 O
couples O
in O
the O
control O
group O
and O
112 O
couples O
in O
the O
experimental O
group O
. O

Primary O
end O
point O
was O
progression-free O
survival O
( O
PFS O
) O
. O

An B-Claim
antidepressant I-Claim
should I-Claim
be I-Claim
considered I-Claim
for I-Claim
early I-Claim
stage I-Claim
breast I-Claim
cancer I-Claim
patients I-Claim
with I-Claim
depressive I-Claim
symptoms I-Claim
who I-Claim
are I-Claim
receiving I-Claim
adjuvant I-Claim
treatment I-Claim
. I-Claim

To O
compare O
the O
efficacy O
of O
low-frequency O
low-intensity O
electrotherapy O
and O
manual O
lymphatic O
drainage O
in O
the O
treatment O
of O
chronic O
upper O
limb O
breast O
cancer-related O
lymphoedema O
. O

A B-Premise
statistically I-Premise
significant I-Premise
improvement I-Premise
in I-Premise
resilience I-Premise
, I-Premise
perceived I-Premise
stress I-Premise
, I-Premise
anxiety I-Premise
, I-Premise
and I-Premise
overall I-Premise
quality I-Premise
of I-Premise
life I-Premise
at I-Premise
12 I-Premise
weeks I-Premise
, I-Premise
compared I-Premise
with I-Premise
baseline I-Premise
was I-Premise
observed I-Premise
in I-Premise
the I-Premise
study I-Premise
arm I-Premise
. I-Premise

No B-Premise
significant I-Premise
main I-Premise
effect I-Premise
of I-Premise
the I-Premise
interventions I-Premise
emerged I-Premise
on I-Premise
cancer-specific I-Premise
distress I-Premise
, I-Premise
but B-Premise
EDU I-Premise
prompted I-Premise
greater I-Premise
reduction I-Premise
in I-Premise
this I-Premise
outcome I-Premise
relative I-Premise
to I-Premise
CTL I-Premise
at I-Premise
6 I-Premise
months I-Premise
for I-Premise
patients I-Premise
who I-Premise
felt I-Premise
more I-Premise
prepared I-Premise
for I-Premise
re-entry I-Premise
. I-Premise

In O
view O
of O
the O
improvements O
in O
overall O
and O
progression-free O
survival O
noted O
with O
pemetrexed O
maintenance O
therapy O
, O
such B-Claim
treatment I-Claim
is I-Claim
an I-Claim
option I-Claim
for I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
non-squamous I-Claim
NSCLC I-Claim
who I-Claim
have I-Claim
not I-Claim
progressed I-Claim
after I-Claim
platinum-based I-Claim
induction I-Claim
therapy I-Claim
. I-Claim

Interestingly B-Claim
, I-Claim
the I-Claim
QOL I-Claim
response I-Claim
analysis I-Claim
also I-Claim
showed I-Claim
that I-Claim
aggressive I-Claim
premedication I-Claim
regimens I-Claim
appear I-Claim
to I-Claim
ameliorate I-Claim
potential I-Claim
negative I-Claim
effects I-Claim
of I-Claim
DPPE I-Claim
on I-Claim
emesis I-Claim
and I-Claim
nausea I-Claim
as I-Claim
measured I-Claim
by I-Claim
patient I-Claim
assessed I-Claim
QOL I-Claim
. I-Claim

In B-Premise
addition I-Premise
, I-Premise
combination I-Premise
therapy I-Premise
showed I-Premise
greater I-Premise
efficacy I-Premise
in I-Premise
the I-Premise
patients I-Premise
with I-Premise
high I-Premise
levels I-Premise
of I-Premise
VEGF I-Premise
expression I-Premise
( I-Premise
p I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

Effects O
varied O
by O
intervention O
dose O
. O

The O
aim O
of O
this O
study O
was O
to O
compare O
the O
analgesic O
and O
adverse O
effects O
, O
doses O
, O
as O
well O
as O
cost O
of O
opioid O
drugs O
, O
supportive O
drug O
therapy O
and O
other O
analgesic O
drugs O
in O
patients O
treated O
with O
oral O
sustained-release O
morphine O
, O
transdermal O
fentanyl O
, O
and O
oral O
methadone O
. O

Thirty-six O
patients O
with O
local-regional O
advanced O
H O
& O
amp O
";" O
N O
cancer O
receiving O
chemoradiationtherapy O
( O
CRT O
) O
were O
randomized O
to O
receive O
either O
placebo O
or O
rhDNase O
. O

MH O
and O
QOL O
were O
assessed O
with O
standardized O
questionnaires O
at O
baseline O
";" O
cycle O
4 O
, O
day O
1 O
";" O
and O
every O
6 O
months O
through O
24 O
months O
. O

Dose O
escalation O
was O
achieved O
in O
77 O
% O
of O
patients O
who O
had O
≥1 O
cycle O
. O

GPX1 B-Claim
may I-Claim
be I-Claim
an I-Claim
inherited I-Claim
factor I-Claim
in I-Claim
predicting I-Claim
patients I-Claim
' I-Claim
QOL I-Claim
. I-Claim

A O
prospective O
randomized O
study O
was O
conducted O
from O
January O
2003 O
. O

This O
double-blind O
phase O
III O
trial O
randomly O
assigned O
731 O
patients O
with O
NSCLC O
who O
had O
progressed O
after O
prior O
chemotherapy O
to O
erlotinib O
150 O
mg O
daily O
or O
placebo O
, O
with O
survival O
as O
the O
primary O
study O
outcome O
. O

The O
intervention O
was O
delivered O
through O
the O
University O
of O
California O
at O
San O
Diego O
";" O
participants O
received O
ten O
phone O
calls O
over O
the O
course O
of O
the O
16-week O
intervention O
. O

Fatigue B-Premise
was I-Premise
lower I-Premise
at I-Premise
1 I-Premise
year I-Premise
than I-Premise
before I-Premise
CTX I-Premise
";" I-Premise
no B-Premise
group I-Premise
effects I-Premise
were I-Premise
found I-Premise
. I-Premise

There B-Premise
was I-Premise
a I-Premise
significant I-Premise
improvement I-Premise
in I-Premise
overall I-Premise
quality I-Premise
of I-Premise
life I-Premise
between I-Premise
the I-Premise
two I-Premise
treatment I-Premise
arms I-Premise
in I-Premise
favor I-Premise
of I-Premise
the I-Premise
r-HuEPO-treated I-Premise
group I-Premise
. I-Premise

The B-Premise
corresponding I-Premise
mean I-Premise
amounts I-Premise
of I-Premise
residual I-Premise
contrast-enhancing I-Premise
tumor I-Premise
tissue I-Premise
were I-Premise
29.2 I-Premise
and I-Premise
24.4 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
. I-Premise

To O
address O
this O
barrier O
, O
we O
examined O
the O
ability O
of O
an O
easily O
accessible O
online O
CBT-I O
program O
to O
improve O
insomnia O
symptoms O
in O
cancer O
survivors O
. O

Patients B-Premise
in I-Premise
the I-Premise
NGT I-Premise
group I-Premise
reported I-Premise
significantly I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
better I-Premise
scores I-Premise
of I-Premise
QoL I-Premise
at I-Premise
both I-Premise
6 I-Premise
months I-Premise
and I-Premise
1 I-Premise
year I-Premise
. I-Premise

An O
additional O
281 O
men O
were O
included O
in O
a O
population-based O
control O
group O
matched O
for O
region O
and O
age O
. O

Group O
1 O
received O
20 O
mg O
of O
CRO O
, O
group O
2 O
received O
10 O
mg O
of O
CRO O
, O
and O
group O
3 O
received O
a O
placebo O
at O
1 O
hour O
before O
transarterial O
chemoembolization O
( O
T O
( O
0 O
) O
) O
and O
12 O
( O
T O
( O
12 O
) O
) O
and O
24 O
( O
T O
( O
24 O
) O
) O
hours O
after O
T O
( O
0 O
) O
. O

Intravenous O
5-FU O
and O
oral O
doxifluridine O
were O
compared O
with O
respect O
to O
therapeutic O
efficacy O
, O
drug O
toxicity O
, O
and O
quality O
of O
life O
. O

In B-Premise
the I-Premise
IAD I-Premise
group I-Premise
, I-Premise
a I-Premise
similar I-Premise
trend I-Premise
was I-Premise
seen I-Premise
. I-Premise

Lymphedema O
was O
assessed O
by O
arm O
circumference O
and O
measurement O
of O
arm O
volume O
by O
water O
displacement O
. O

These B-Premise
findings I-Premise
were I-Premise
associated I-Premise
with I-Premise
higher I-Premise
post-procedure I-Premise
pain I-Premise
scores I-Premise
in I-Premise
the I-Premise
SEMS I-Premise
patient I-Premise
group I-Premise
( I-Premise
mean I-Premise
difference I-Premise
of I-Premise
the I-Premise
European I-Premise
Organisation I-Premise
for I-Premise
Research I-Premise
and I-Premise
Treatment I-Premise
of I-Premise
Cancer I-Premise
QLQ I-Premise
C-30 I-Premise
pain I-Premise
symptom I-Premise
score I-Premise
at I-Premise
week I-Premise
1=11.13 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
2.89-19.4 I-Premise
";" I-Premise
P=0.01 I-Premise
) I-Premise
. I-Premise

Topical O
photodynamic O
therapy O
( O
PDT O
) O
with O
aminolevulinic O
acid O
( O
ALA O
) O
and O
5 O
% O
imiquimod O
cream O
are O
effective O
therapies O
for O
the O
treatment O
of O
actinic O
keratoses O
( O
AKs O
) O
, O
but O
no O
split-face O
studies O
directly O
comparing O
these O
treatment O
options O
are O
available O
in O
the O
literature O
. O

The B-Claim
CCSP I-Claim
as I-Claim
an I-Claim
effective I-Claim
coping I-Claim
intervention I-Claim
has I-Claim
potential I-Claim
as I-Claim
a I-Claim
self-management I-Claim
program I-Claim
for I-Claim
breast I-Claim
cancer I-Claim
survivors I-Claim
. I-Claim

The O
CMA O
intervention O
, O
delivered O
by O
a O
nurse O
practitioner O
, O
focused O
on O
symptom O
assessment O
, O
education O
, O
counseling O
and O
, O
as O
appropriate O
, O
specific O
pharmacologic O
and O
behavioral O
interventions O
for O
each O
of O
the O
three O
target O
symptoms O
. O

Endpoints O
were O
survival O
, O
safety O
, O
efficacy O
, O
and O
quality O
of O
life O
. O

This B-Claim
study I-Claim
demonstrated I-Claim
no I-Claim
advantage I-Claim
in I-Claim
RR I-Claim
, I-Claim
RD I-Claim
, I-Claim
or I-Claim
PFS I-Claim
but I-Claim
significantly I-Claim
superior I-Claim
OS I-Claim
for I-Claim
DPPE I-Claim
plus I-Claim
DOX I-Claim
. I-Claim

This B-Premise
negative I-Premise
impact I-Premise
tended I-Premise
to I-Premise
last I-Premise
longer I-Premise
in I-Premise
the I-Premise
HDC I-Premise
group I-Premise
, I-Premise
as I-Premise
for I-Premise
most I-Premise
of I-Premise
the I-Premise
QLQ-C30 I-Premise
scales I-Premise
, I-Premise
the I-Premise
QOL I-Premise
scores I-Premise
of I-Premise
HDC I-Premise
patients I-Premise
tend I-Premise
to I-Premise
improve I-Premise
at I-Premise
a I-Premise
slower I-Premise
rate I-Premise
than I-Premise
that I-Premise
of I-Premise
patients I-Premise
receiving I-Premise
standard I-Premise
chemotherapy I-Premise
. I-Premise

A O
total O
of O
306 O
patients O
with O
localized O
prostate O
cancer O
were O
randomized O
. O

Hormonal B-Claim
breast I-Claim
cancer I-Claim
treatment I-Claim
increases I-Claim
menopausal I-Claim
symptoms I-Claim
in I-Claim
women I-Claim
. I-Claim

This O
analysis O
investigated O
the O
treatment O
effects O
on O
health-related O
quality O
of O
life O
( O
HRQOL O
) O
. O

PF B-Premise
change I-Premise
scores I-Premise
were I-Premise
-3.9 I-Premise
for I-Premise
cetuximab I-Premise
and I-Premise
-8.6 I-Premise
for I-Premise
BSC I-Premise
( I-Premise
P I-Premise
= I-Premise
.046 I-Premise
) I-Premise
at I-Premise
8 I-Premise
weeks I-Premise
and I-Premise
were I-Premise
-5.9 I-Premise
and I-Premise
-12.5 I-Premise
for I-Premise
cetuximab I-Premise
and I-Premise
BSC I-Premise
, I-Premise
respectively I-Premise
, I-Premise
( I-Premise
P I-Premise
= I-Premise
.027 I-Premise
) I-Premise
at I-Premise
16 I-Premise
weeks I-Premise
. I-Premise

Breast O
cancer O
outcomes O
included O
recurrence O
as O
well O
as O
disease-free O
and O
overall O
survival O
. O

The B-Premise
observed I-Premise
mean I-Premise
difference I-Premise
in I-Premise
the I-Premise
average I-Premise
pain I-Premise
score I-Premise
between I-Premise
duloxetine I-Premise
and I-Premise
placebo I-Premise
was I-Premise
0.73 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.26-1.20 I-Premise
) I-Premise
. I-Premise

Subcutaneous B-Claim
interleukin-2 I-Claim
and/or I-Claim
interferon-alfa I-Claim
provide I-Claim
no I-Claim
survival I-Claim
benefit I-Claim
in I-Claim
metastatic I-Claim
renal I-Claim
cancers I-Claim
of I-Claim
intermediate I-Claim
prognosis I-Claim
, I-Claim
and I-Claim
they I-Claim
induce I-Claim
a I-Claim
significant I-Claim
risk I-Claim
of I-Claim
toxicity I-Claim
. I-Claim

In B-Claim
cachectic I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
cancer I-Claim
, I-Claim
oral I-Claim
melatonin I-Claim
20 I-Claim
mg I-Claim
at I-Claim
night I-Claim
did I-Claim
not I-Claim
improve I-Claim
appetite I-Claim
, I-Claim
weight I-Claim
, I-Claim
or I-Claim
quality I-Claim
of I-Claim
life I-Claim
compared I-Claim
with I-Claim
placebo I-Claim
. I-Claim

QOL O
evaluations O
were O
available O
for O
199 O
patients O
. O

Although B-Claim
TMZ I-Claim
( I-Claim
both I-Claim
arms I-Claim
combined I-Claim
) I-Claim
did I-Claim
not I-Claim
show I-Claim
a I-Claim
clear I-Claim
benefit I-Claim
compared I-Claim
with I-Claim
PCV I-Claim
, I-Claim
comparison I-Claim
of I-Claim
the I-Claim
TMZ I-Claim
schedules I-Claim
demonstrated I-Claim
that I-Claim
the I-Claim
21-day I-Claim
schedule I-Claim
was I-Claim
inferior I-Claim
to I-Claim
the I-Claim
5-day I-Claim
schedule I-Claim
in I-Claim
this I-Claim
setting I-Claim
. I-Claim

It B-Claim
is I-Claim
a I-Claim
safe I-Claim
, I-Claim
effective I-Claim
and I-Claim
durable I-Claim
treatment I-Claim
for I-Claim
vasomotor I-Claim
symptoms I-Claim
secondary I-Claim
to I-Claim
long-term I-Claim
antiestrogen I-Claim
hormone I-Claim
use I-Claim
in I-Claim
patients I-Claim
with I-Claim
breast I-Claim
cancer I-Claim
. I-Claim

Adverse B-Claim
events I-Claim
during I-Claim
temozolomide I-Claim
treatment I-Claim
included I-Claim
thrombocytopenia I-Claim
, I-Claim
nausea I-Claim
, I-Claim
vomiting I-Claim
, I-Claim
anorexia I-Claim
, I-Claim
constipation I-Claim
, I-Claim
alopecia I-Claim
, I-Claim
headache I-Claim
, I-Claim
fatigue I-Claim
, I-Claim
and I-Claim
convulsions I-Claim
. I-Claim

A B-Premise
similar I-Premise
pattern I-Premise
was I-Premise
observed I-Premise
for I-Premise
knee I-Premise
extensor I-Premise
muscles I-Premise
( I-Premise
P I-Premise
=.02 I-Premise
) I-Premise
. I-Premise

The O
control O
group O
received O
no O
advice O
about O
exercise O
. O

The O
purpose O
of O
this O
2-group O
randomized O
controlled O
pilot O
feasibility O
study O
was O
to O
test O
short-term O
effects O
of O
a O
12-week O
Mindful O
Movement O
Program O
( O
MMP O
) O
intervention O
combining O
mindfulness O
with O
self-directed O
movement O
on O
QOL O
and O
mindfulness O
in O
female O
BCSs O
50 O
years O
or O
older O
and O
at O
12 O
months O
or O
more O
following O
treatment O
. O

In O
445 O
randomly O
assigned O
and O
treated O
patients O
( O
DCF O
= O
221 O
";" O
CF O
= O
224 O
) O
, O
TTP O
was O
longer O
with O
DCF O
versus O
CF O
( O
32 O
% O
risk O
reduction O
";" O
log-rank O
P O
< O
.001 O
) O
. O

Eighty O
participants O
completed O
all O
follow-ups O
. O

There B-Premise
was I-Premise
a I-Premise
significant I-Premise
deterioration I-Premise
in I-Premise
QOL I-Premise
and I-Premise
an I-Premise
increase I-Premise
in I-Premise
depression I-Premise
associated I-Premise
with I-Premise
IFN5 I-Premise
but I-Premise
no I-Premise
change I-Premise
was I-Premise
noted I-Premise
with I-Premise
IFN1 I-Premise
. I-Premise

We O
conducted O
a O
randomized O
pilot O
study O
in O
patients O
treated O
with O
four O
fractions O
of O
lung O
SBRT O
delivered O
over O
4 O
or O
over O
11 O
days O
. O

Secondary O
outcomes O
of O
self-reported O
end-of-life O
experiences O
were O
assessed O
in O
a O
survey O
that O
was O
undertaken O
after O
the O
completion O
of O
the O
study O
. O

Our B-Claim
findings I-Claim
showed I-Claim
no I-Claim
evidence I-Claim
of I-Claim
a I-Claim
survival I-Claim
benefit I-Claim
with I-Claim
early I-Claim
treatment I-Claim
of I-Claim
relapse I-Claim
on I-Claim
the I-Claim
basis I-Claim
of I-Claim
a I-Claim
raised I-Claim
CA125 I-Claim
concentration I-Claim
alone I-Claim
, I-Claim
and B-Claim
therefore I-Claim
the I-Claim
value I-Claim
of I-Claim
routine I-Claim
measurement I-Claim
of I-Claim
CA125 I-Claim
in I-Claim
the I-Claim
follow-up I-Claim
of I-Claim
patients I-Claim
with I-Claim
ovarian I-Claim
cancer I-Claim
who I-Claim
attain I-Claim
a I-Claim
complete I-Claim
response I-Claim
after I-Claim
first-line I-Claim
treatment I-Claim
is I-Claim
not I-Claim
proven I-Claim
. I-Claim

Three O
hundred O
two O
outpatients O
with O
breast O
cancer O
participated O
. O

Median B-Premise
survivals I-Premise
for I-Premise
marimastat I-Premise
and I-Premise
placebo I-Premise
patients I-Premise
were I-Premise
9.3 I-Premise
months I-Premise
and I-Premise
9.7 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P I-Premise
=.90 I-Premise
) I-Premise
. I-Premise

Testosterone O
kinetics O
and O
QOL O
were O
also O
evaluated O
. O

Median O
follow-up O
was O
26 O
months O
. O

For B-Premise
willingness-to-pay I-Premise
between I-Premise
$ I-Premise
5000 I-Premise
and I-Premise
$ I-Premise
40 I-Premise
0 I-Premise
per I-Premise
quality-adjusted I-Premise
life I-Premise
year I-Premise
, I-Premise
the I-Premise
single-fraction I-Premise
schedule I-Premise
was I-Premise
statistically I-Premise
significantly I-Premise
more I-Premise
cost-effective I-Premise
than I-Premise
the I-Premise
multiple-fraction I-Premise
schedule I-Premise
( I-Premise
P I-Premise
< I-Premise
or I-Premise
=.05 I-Premise
) I-Premise
. I-Premise

Serum B-Premise
albumin I-Premise
concentration I-Premise
declined I-Premise
by I-Premise
-1.2 I-Premise
g/L I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI= I-Premise
-2.0 I-Premise
to I-Premise
-0.4 I-Premise
) I-Premise
per I-Premise
4 I-Premise
weeks I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
but I-Premise
remained I-Premise
stable I-Premise
( I-Premise
0.0 I-Premise
g/L I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
-0.3 I-Premise
to I-Premise
+0.3 I-Premise
) I-Premise
in I-Premise
the I-Premise
ATP I-Premise
group I-Premise
( I-Premise
P I-Premise
=.006 I-Premise
) I-Premise
. I-Premise

Both O
treatments O
then O
were O
followed O
by O
carboplatin O
to O
an O
area O
under O
the O
plasma O
concentration-time O
curve O
of O
5 O
. O

Nonetheless B-Claim
, I-Claim
it I-Claim
is I-Claim
apparent I-Claim
that I-Claim
these I-Claim
first-generation I-Claim
regimens I-Claim
must I-Claim
be I-Claim
applied I-Claim
judiciously I-Claim
, I-Claim
and O
thus B-Claim
we I-Claim
view I-Claim
efforts I-Claim
at I-Claim
better I-Claim
patient I-Claim
selection I-Claim
and I-Claim
the I-Claim
development I-Claim
of I-Claim
more I-Claim
tolerable I-Claim
therapies I-Claim
as I-Claim
higher I-Claim
priorities I-Claim
than I-Claim
carrying I-Claim
either I-Claim
of I-Claim
these I-Claim
regimens I-Claim
to I-Claim
phase I-Claim
III I-Claim
evaluation I-Claim
in I-Claim
the I-Claim
cooperative I-Claim
group I-Claim
setting I-Claim
. I-Claim

Randomized O
, O
double-blinded O
, O
placebo-controlled O
. O

Pain O
was O
assessed O
with O
the O
BPI-SF O
questionnaire O
, O
and O
health-related O
quality O
of O
life O
( O
HRQoL O
) O
with O
the O
Functional O
Assessment O
of O
Cancer O
Therapy-Prostate O
( O
FACT-P O
) O
questionnaire O
. O

To O
determine O
the O
efficacy O
of O
topotecan O
in O
combination O
with O
standard O
chemotherapy O
in O
previously O
untreated O
patients O
with O
extensive-stage O
small-cell O
lung O
cancer O
( O
SCLC O
) O
, O
the O
Eastern O
Cooperative O
Oncology O
Group O
( O
ECOG O
) O
conducted O
a O
phase O
III O
trial O
. O

Treatment B-Premise
was I-Premise
associated I-Premise
with I-Premise
significant I-Premise
improvements I-Premise
in I-Premise
pain I-Premise
( I-Premise
P=.024 I-Premise
) I-Premise
and I-Premise
swelling I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

The O
primary O
end O
points O
were O
response O
and O
overall O
survival O
time O
. O

They O
were O
randomized O
to O
receive O
marimastat O
10 O
mg O
or O
placebo O
orally O
bid O
for O
up O
to O
2 O
years O
. O

Outcomes O
were O
compared O
between O
groups O
using O
analysis O
of O
covariance O
adjusted O
for O
baseline O
values O
. O

Median O
follow-up O
was O
13.3 O
years O
. O

Up O
to O
December O
2006 O
, O
eighty-seven O
patients O
of O
stage O
II O
and O
III O
, O
including O
71 O
patients O
of O
middle O
third O
lesions O
and O
16 O
lower O
third O
lesions O
were O
enrolled O
. O

From O
January O
, O
2001 O
, O
until O
August O
, O
2005 O
, O
504 O
patients O
were O
randomly O
assigned O
to O
pamidronate O
30 O
mg O
or O
90 O
mg O
( O
252 O
in O
each O
group O
) O
. O

Multimodality B-Claim
therapies I-Claim
for I-Claim
cachexia I-Claim
ideally I-Claim
should I-Claim
be I-Claim
introduced I-Claim
within I-Claim
a I-Claim
context I-Claim
of I-Claim
" I-Claim
best I-Claim
supportive I-Claim
care I-Claim
" I-Claim
that I-Claim
includes I-Claim
optimal I-Claim
symptom I-Claim
management I-Claim
and I-Claim
careful I-Claim
psychosocial I-Claim
counseling I-Claim
. I-Claim

Treatment B-Premise
effects I-Premise
favored I-Premise
castration I-Premise
for I-Premise
both I-Premise
endpoints I-Premise
( I-Premise
P I-Premise
< I-Premise
or I-Premise
= I-Premise
0.002 I-Premise
) I-Premise
, I-Premise
with I-Premise
hazard I-Premise
ratios I-Premise
( I-Premise
bicalutamide I-Premise
: I-Premise
castration I-Premise
) I-Premise
of I-Premise
1.54 I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
, I-Premise
1.18 I-Premise
to I-Premise
2.00 I-Premise
) I-Premise
for I-Premise
time I-Premise
to I-Premise
treatment I-Premise
failure I-Premise
and I-Premise
1.6 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
1.19 I-Premise
to I-Premise
2.15 I-Premise
) I-Premise
for I-Premise
time I-Premise
to I-Premise
disease I-Premise
progression I-Premise
. I-Premise

The O
study O
was O
completed O
by O
the O
actor O
as O
a O
descriptive O
, O
explorative O
study O
on O
the O
impact O
of O
" O
laying O
on O
of O
hands O
" O
. O

Erlotinib B-Claim
was I-Claim
generally I-Claim
well I-Claim
tolerated I-Claim
and I-Claim
had I-Claim
no I-Claim
negative I-Claim
impact I-Claim
on I-Claim
QoL I-Claim
in I-Claim
this I-Claim
subpopulation I-Claim
. I-Claim

At B-Premise
enrollment I-Premise
, I-Premise
mood I-Premise
and I-Premise
emotional I-Premise
functioning I-Premise
were I-Premise
similar I-Premise
among I-Premise
all I-Premise
patients I-Premise
, I-Premise
with I-Premise
no I-Premise
differences I-Premise
by I-Premise
type I-Premise
of I-Premise
treatment I-Premise
received I-Premise
. I-Premise

Evidence B-Premise
of I-Premise
a I-Premise
homeopathic I-Premise
" I-Premise
drug I-Premise
proving I-Premise
" I-Premise
in I-Premise
the I-Premise
subjects I-Premise
receiving I-Premise
the I-Premise
homeopathic I-Premise
combination I-Premise
medicine I-Premise
who I-Premise
were I-Premise
not I-Premise
taking I-Premise
tamoxifen I-Premise
also I-Premise
was I-Premise
found I-Premise
. I-Premise

The O
finding O
of O
a O
decrease O
in O
contralateral O
breast O
cancer O
incidence O
following O
tamoxifen O
administration O
for O
adjuvant O
therapy O
led O
to O
the O
concept O
that O
the O
drug O
might O
play O
a O
role O
in O
breast O
cancer O
prevention O
. O

Fifty O
GI O
cancer O
patients O
received O
postoperative O
7 O
days O
of O
isocaloric O
and O
isonitrogenous O
TPN O
after O
operation O
. O

Overall B-Premise
, I-Premise
the I-Premise
antiandrogen I-Premise
was I-Premise
well I-Premise
tolerated I-Premise
compared I-Premise
with I-Premise
castration I-Premise
";" I-Premise
with B-Premise
bicalutamide I-Premise
, I-Premise
hot I-Premise
flushes I-Premise
occurred I-Premise
less I-Premise
often I-Premise
and I-Premise
breast I-Premise
tenderness I-Premise
and I-Premise
gynecomastia I-Premise
more I-Premise
often I-Premise
. I-Premise

Based O
on O
pattern-mixture O
models O
, O
patients O
who O
dropped O
out O
early O
had O
worse O
QL2 O
decline O
on O
both O
treatments O
. O

Of O
5,187 O
randomly O
assigned O
women O
in O
the O
trial O
, O
3,612 O
( O
69.9 O
% O
) O
participated O
in O
the O
QOL O
substudy O
: O
1,799 O
were O
allocated O
to O
placebo O
and O
1,813 O
were O
allocated O
to O
letrozole O
. O

Median B-Premise
time I-Premise
to I-Premise
progress I-Premise
for I-Premise
radiotherapy I-Premise
only I-Premise
and I-Premise
radiotherapy I-Premise
and I-Premise
estramustin I-Premise
group I-Premise
in I-Premise
grade I-Premise
III I-Premise
tumours I-Premise
was I-Premise
6.5 I-Premise
and I-Premise
10.1 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Fulvestrant B-Claim
500 I-Claim
mg I-Claim
was I-Claim
well I-Claim
tolerated I-Claim
with I-Claim
no I-Claim
dose-dependent I-Claim
adverse I-Claim
events I-Claim
. I-Claim

Those B-Claim
who I-Claim
respond I-Claim
to I-Claim
gemcitabine I-Claim
may I-Claim
experience I-Claim
a I-Claim
slight I-Claim
slowing I-Claim
of I-Claim
functional I-Claim
deterioration I-Claim
. I-Claim

Response B-Claim
to I-Claim
gemcitabine I-Claim
treatment I-Claim
in I-Claim
APC I-Claim
is I-Claim
not I-Claim
associated I-Claim
with I-Claim
appreciable I-Claim
improvement I-Claim
of I-Claim
global I-Claim
HRQOL I-Claim
. I-Claim

Overall B-Premise
survival I-Premise
was I-Premise
longer I-Premise
with I-Premise
DCF I-Premise
versus I-Premise
CF I-Premise
( I-Premise
23 I-Premise
% I-Premise
risk I-Premise
reduction I-Premise
";" I-Premise
log-rank I-Premise
P I-Premise
= I-Premise
.02 I-Premise
) I-Premise
. I-Premise

A O
well-tolerated O
and O
effective O
mind-body O
treatment O
for O
hot O
flashes O
would O
be O
of O
great O
value O
. O

Survival O
was O
analyzed O
on O
an O
intent-to-treat O
basis O
. O

Patients O
completed O
the O
Lung O
Cancer O
Symptom O
Scale O
( O
LCSS O
) O
at O
baseline O
, O
after O
each O
cycle O
, O
and O
post-discontinuation O
. O

Thalidomide B-Premise
was I-Premise
associated I-Premise
with I-Premise
an I-Premise
increased I-Premise
risk I-Premise
of I-Premise
having I-Premise
a I-Premise
thrombotic I-Premise
event I-Premise
, I-Premise
mainly I-Premise
pulmonary I-Premise
embolus I-Premise
and I-Premise
deep I-Premise
vein I-Premise
thrombosis I-Premise
( I-Premise
19 I-Premise
% I-Premise
thalidomide I-Premise
vs I-Premise
10 I-Premise
% I-Premise
placebo I-Premise
";" I-Premise
HR I-Premise
= I-Premise
2.13 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
1.41 I-Premise
to I-Premise
3.20 I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

Integration B-Claim
of I-Claim
the I-Claim
PMP I-Claim
into I-Claim
routine I-Claim
clinical I-Claim
work I-Claim
may I-Claim
help I-Claim
to I-Claim
improve I-Claim
the I-Claim
standard I-Claim
of I-Claim
care I-Claim
for I-Claim
cancer I-Claim
patients I-Claim
. I-Claim

The B-Claim
results I-Claim
of I-Claim
this I-Claim
study I-Claim
have I-Claim
demonstrated I-Claim
the I-Claim
importance I-Claim
of I-Claim
baseline I-Claim
HRQOL I-Claim
as I-Claim
a I-Claim
significant I-Claim
and I-Claim
independent I-Claim
predictor I-Claim
of I-Claim
LRC I-Claim
in I-Claim
patients I-Claim
with I-Claim
locally I-Claim
advanced I-Claim
head I-Claim
and I-Claim
neck I-Claim
cancer I-Claim
. I-Claim

Subdomain B-Premise
analysis I-Premise
revealed I-Premise
a I-Premise
clinically I-Premise
moderate I-Premise
improvement I-Premise
from I-Premise
baseline I-Premise
for I-Premise
LAC I-Premise
in I-Premise
total I-Premise
QOL I-Premise
index I-Premise
at I-Premise
18 I-Premise
months I-Premise
( I-Premise
P I-Premise
= I-Premise
0.02 I-Premise
) I-Premise
as I-Premise
well I-Premise
as I-Premise
other I-Premise
small I-Premise
symptomatic I-Premise
improvements I-Premise
. I-Premise

At B-Premise
4 I-Premise
months I-Premise
, I-Premise
J-pouch I-Premise
patients I-Premise
had I-Premise
10.3 I-Premise
% I-Premise
less I-Premise
stool I-Premise
fragmentation I-Premise
but I-Premise
poorer I-Premise
stool I-Premise
deferment I-Premise
and I-Premise
more I-Premise
nocturnal I-Premise
leakage I-Premise
. I-Premise

Data O
on O
survival O
time O
and O
medical O
care O
resource O
use O
were O
prospectively O
collected O
in O
the O
trial O
. O

This O
triple O
blinded O
study O
randomized O
220 O
HNC O
patients O
scheduled O
for O
CRT O
( O
three O
weekly O
Cisplatin O
+ O
RT O
= O
66 O
Gray O
( O
2 O
Gy/session O
) O
, O
five O
fractions/week O
for O
6.5 O
weeks O
, O
total O
33 O
fractions O
) O
into O
laser O
( O
110 O
) O
and O
placebo O
( O
110 O
) O
groups O
. O

The O
follow-up O
assessment O
rate O
was O
73 O
% O
( O
329 O
of O
450 O
) O
. O

The O
QoL O
was O
evaluated O
by O
the O
Spitzer O
QL-Index O
and O
by O
the O
EORTC O
QLQ-C30+LC O
13 O
questionnaires O
before O
chemotherapy O
, O
after O
one O
cycle O
, O
after O
three O
cycles O
, O
and O
then O
every O
6 O
weeks O
in O
the O
first O
6 O
months O
and O
every O
3 O
months O
thenafter O
. O

CONNECT B-Claim
has I-Claim
shown I-Claim
promising I-Claim
indications I-Claim
on I-Claim
health I-Claim
system I-Claim
and I-Claim
patient I-Claim
outcomes I-Claim
that I-Claim
warrant I-Claim
a I-Claim
larger I-Claim
study I-Claim
to I-Claim
further I-Claim
investigate I-Claim
the I-Claim
potential I-Claim
of I-Claim
this I-Claim
intervention I-Claim
. I-Claim

The B-Claim
role I-Claim
of I-Claim
adjuvant I-Claim
chemotherapy I-Claim
in I-Claim
postmenopausal I-Claim
patients I-Claim
with I-Claim
lymph I-Claim
node-negative I-Claim
breast I-Claim
cancer I-Claim
is I-Claim
controversial I-Claim
. I-Claim

The O
study O
accrued O
344 O
patients O
";" O
330 O
were O
assessable O
for O
efficacy O
and O
305 O
were O
assessable O
for O
QOL O
. O

Cognitive O
function O
was O
assessed O
by O
Executive O
Interview O
( O
EXIT25 O
) O
and O
Clock O
Drawing O
Tasks O
";" O
mood O
by O
Profile O
of O
Mood O
States O
";" O
anemia-related O
symptoms O
, O
including O
fatigue O
, O
by O
the O
Functional O
Assessment O
of O
Cancer O
Therapy-Anemia O
( O
FACT-An O
) O
subscale O
";" O
and O
QOL O
by O
Linear O
Analog O
Scale O
Assessment O
. O

Distress B-Claim
reduction I-Claim
is I-Claim
highlighted I-Claim
as I-Claim
an I-Claim
important I-Claim
mechanism I-Claim
by I-Claim
which I-Claim
health I-Claim
can I-Claim
be I-Claim
improved I-Claim
. I-Claim

Analyses O
were O
performed O
on O
an O
intention-to-treat O
basis O
. O

Although O
numerous O
treatment O
modalities O
have O
been O
explored O
in O
patients O
with O
advanced O
HCC O
, O
the O
therapeutic O
options O
are O
still O
limited O
. O

Oral O
morphine O
was O
used O
as O
breakthrough O
pain O
medication O
during O
opioid O
titration O
. O

Hospital B-Premise
stay I-Premise
for I-Premise
patients I-Premise
who I-Premise
received I-Premise
EOF I-Premise
( I-Premise
n=71 I-Premise
) I-Premise
was I-Premise
4.7 I-Premise
vs. I-Premise
5.8 I-Premise
days I-Premise
for I-Premise
the I-Premise
TOF I-Premise
group I-Premise
( I-Premise
n=72 I-Premise
) I-Premise
( I-Premise
P=0.006 I-Premise
) I-Premise
. I-Premise

No B-Claim
substantive I-Claim
differences I-Claim
were I-Claim
detected I-Claim
between I-Claim
outcomes I-Claim
of I-Claim
embolization I-Claim
with I-Claim
PVA I-Claim
particles I-Claim
or I-Claim
tris-acryl I-Claim
gelatin I-Claim
microspheres I-Claim
. I-Claim

Administration O
of O
ESAs O
on O
a O
synchronous O
schedule O
with O
chemotherapy O
administration O
could O
benefit O
patients O
by O
reducing O
clinic O
visits O
and O
potentially O
enhancing O
on-time O
chemotherapy O
delivery O
. O

Evaluated O
outcomes O
included O
pain O
intensity O
, O
need O
for O
change O
in O
therapy O
, O
quality O
of O
life O
, O
Karnofsky O
Performance O
Status O
, O
general O
condition O
of O
the O
patient O
, O
and O
adverse O
events O
. O

Trained B-Premise
versus I-Premise
control I-Premise
patients I-Premise
reported I-Premise
reduced I-Premise
barriers I-Premise
to I-Premise
pain I-Premise
relief I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
, I-Premise
lower I-Premise
usual I-Premise
pain I-Premise
( I-Premise
P=.03 I-Premise
) I-Premise
, I-Premise
and I-Premise
greater I-Premise
opioid I-Premise
use I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

Survival B-Premise
and I-Premise
hospital I-Premise
stay I-Premise
did I-Premise
not I-Premise
differ I-Premise
among I-Premise
the I-Premise
groups I-Premise
, I-Premise
whereas I-Premise
overall I-Premise
complications I-Premise
were I-Premise
higher I-Premise
on I-Premise
artificial I-Premise
nutrition I-Premise
( I-Premise
P I-Premise
< I-Premise
.05 I-Premise
) I-Premise
. I-Premise

These B-Premise
changes I-Premise
were I-Premise
similar I-Premise
in I-Premise
both I-Premise
groups I-Premise
, I-Premise
indicating I-Premise
that I-Premise
acupuncture I-Premise
was I-Premise
as I-Premise
effective I-Premise
as I-Premise
venlafaxine I-Premise
. I-Premise

Therefore B-Claim
, I-Claim
this I-Claim
regimen I-Claim
is I-Claim
not I-Claim
recommended I-Claim
as I-Claim
standard I-Claim
of I-Claim
care I-Claim
treatment I-Claim
for I-Claim
ovarian I-Claim
cancer I-Claim
. I-Claim

Patients B-Premise
treated I-Premise
with I-Premise
PB I-Premise
experienced I-Premise
more I-Premise
improvement I-Premise
in I-Premise
total I-Premise
FACT-B I-Premise
( I-Premise
Functional I-Premise
Assessment I-Premise
of I-Premise
Cancer I-Premise
Therapy-Breast I-Premise
) I-Premise
( I-Premise
P I-Premise
= I-Premise
.021 I-Premise
) I-Premise
, I-Premise
FACT-B I-Premise
Social/Family I-Premise
Well-being I-Premise
( I-Premise
P I-Premise
= I-Premise
.041 I-Premise
) I-Premise
, I-Premise
and I-Premise
Breast I-Premise
Cancer-Additional I-Premise
Concerns I-Premise
( I-Premise
P I-Premise
= I-Premise
.008 I-Premise
) I-Premise
scores I-Premise
than I-Premise
patients I-Premise
treated I-Premise
with I-Premise
PB+G I-Premise
. I-Premise

Although O
infrequent O
, O
other O
similar O
reports O
highlight O
the O
need O
for O
ongoing O
trials O
evaluating O
erythropoietin O
receptor O
agonists O
to O
ensure O
that O
overall O
survival O
is O
monitored O
closely O
. O

Compared B-Premise
with I-Premise
patients I-Premise
in I-Premise
the I-Premise
TC I-Premise
arm I-Premise
, I-Premise
patients I-Premise
in I-Premise
the I-Premise
TC-Top I-Premise
arm I-Premise
had I-Premise
more I-Premise
grade I-Premise
3-4 I-Premise
hematologic I-Premise
toxic I-Premise
effects I-Premise
( I-Premise
requiring I-Premise
more I-Premise
supportive I-Premise
care I-Premise
) I-Premise
and I-Premise
more I-Premise
grade I-Premise
3-4 I-Premise
infections I-Premise
( I-Premise
5.1 I-Premise
% I-Premise
versus I-Premise
2.7 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
.034 I-Premise
) I-Premise
but I-Premise
did I-Premise
not I-Premise
have I-Premise
a I-Premise
statistically I-Premise
significant I-Premise
increase I-Premise
in I-Premise
febrile I-Premise
neutropenia I-Premise
( I-Premise
3.3 I-Premise
% I-Premise
versus I-Premise
3.1 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
.80 I-Premise
) I-Premise
. I-Premise

The B-Premise
sample I-Premise
size I-Premise
was I-Premise
small I-Premise
, I-Premise
and I-Premise
patients I-Premise
applied I-Premise
a I-Premise
small I-Premise
amount I-Premise
of I-Premise
imiquimod I-Premise
5 I-Premise
% I-Premise
cream I-Premise
( I-Premise
half I-Premise
a I-Premise
sachet I-Premise
) I-Premise
to I-Premise
a I-Premise
large I-Premise
surface I-Premise
area I-Premise
. I-Premise

Grade B-Premise
3 I-Premise
or I-Premise
4 I-Premise
myelosuppressions I-Premise
were I-Premise
more I-Premise
frequent I-Premise
with I-Premise
GC I-Premise
( I-Premise
anaemia I-Premise
: I-Premise
14 I-Premise
% I-Premise
GC I-Premise
vs I-Premise
2 I-Premise
% I-Premise
PE I-Premise
";" I-Premise
leucopenia I-Premise
: I-Premise
32 I-Premise
% I-Premise
GC I-Premise
vs I-Premise
13 I-Premise
% I-Premise
PE I-Premise
";" I-Premise
thrombocytopenia I-Premise
: I-Premise
22 I-Premise
% I-Premise
GC I-Premise
vs I-Premise
4 I-Premise
% I-Premise
PE I-Premise
) I-Premise
, I-Premise
but B-Premise
these I-Premise
were I-Premise
not I-Premise
associated I-Premise
with I-Premise
increased I-Premise
hospital I-Premise
admissions I-Premise
, I-Premise
infections I-Premise
or I-Premise
fatalities I-Premise
. I-Premise

Depression B-Premise
scores I-Premise
yielded I-Premise
a I-Premise
linear I-Premise
interaction I-Premise
comparing I-Premise
UCO I-Premise
and I-Premise
SMEX I-Premise
( I-Premise
p I-Premise
= I-Premise
0.019 I-Premise
) I-Premise
, I-Premise
with I-Premise
decreases I-Premise
in I-Premise
SMEX I-Premise
but I-Premise
not I-Premise
UCO I-Premise
. I-Premise

Patients O
in O
the O
control O
arm O
received O
radiotherapy O
only O
. O

They O
were O
followed O
until O
they O
finished O
primary O
treatment O
( O
enrollment O
) O
, O
at O
which O
time O
they O
completed O
a O
mailed O
baseline O
survey O
that O
included O
standardized O
measures O
of O
quality O
of O
life O
( O
including O
standardized O
scales O
of O
physical O
and O
emotional O
functioning O
) O
, O
mood O
, O
symptoms O
, O
and O
sexual O
functioning O
. O

HRQOL O
was O
assessed O
with O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Core O
Quality O
of O
Life O
Questionnaire O
C30 O
( O
EORTC O
QLQ-C30 O
) O
and O
EORTC O
Lung O
Cancer O
Module O
( O
QLQ-LC13 O
) O
tools O
. O

Patients O
were O
randomly O
assigned O
to O
receive O
: O
docetaxel O
75 O
mg/m2 O
plus O
cisplatin O
75 O
mg/m2 O
, O
every O
3 O
weeks O
( O
DC O
) O
";" O
docetaxel O
75 O
mg/m2 O
and O
carboplatin O
6 O
mg/ml O
min O
, O
every O
3 O
weeks O
( O
DCb O
) O
";" O
or O
vinorelbine O
25 O
mg/m2/week O
plus O
cisplatin O
100 O
mg/m2 O
, O
every O
4 O
weeks O
( O
VC O
) O
. O

Patients B-Premise
who I-Premise
experienced I-Premise
more I-Premise
concentration I-Premise
and I-Premise
memory I-Premise
problems I-Premise
at I-Premise
T1 I-Premise
benefited I-Premise
more I-Premise
from I-Premise
CBT I-Premise
for I-Premise
fatigue I-Premise
and I-Premise
are I-Premise
indicators I-Premise
. I-Premise

Global B-Claim
quality I-Claim
of I-Claim
life I-Claim
did I-Claim
not I-Claim
differ I-Claim
within I-Claim
the I-Claim
three I-Claim
arms I-Claim
. I-Claim

It O
is O
not O
known O
whether O
low-dose O
radioiodine O
( O
1.1 O
GBq O
[ O
30 O
mCi O
] O
) O
is O
as O
effective O
as O
high-dose O
radioiodine O
( O
3.7 O
GBq O
[ O
100 O
mCi O
] O
) O
for O
treating O
patients O
with O
differentiated O
thyroid O
cancer O
or O
whether O
the O
effects O
of O
radioiodine O
( O
especially O
at O
a O
low O
dose O
) O
are O
influenced O
by O
using O
either O
recombinant O
human O
thyrotropin O
( O
thyrotropin O
alfa O
) O
or O
thyroid O
hormone O
withdrawal O
. O

After O
anterior O
resection O
for O
cancer O
, O
patients O
were O
allocated O
to O
either O
J-pouch O
or O
CP-anal O
anastomoses O
. O

Following O
assessment O
of O
mental O
and O
physical O
well-being O
, O
depression O
, O
anxiety O
, O
exercise O
, O
and O
stress O
reduction O
activity O
before O
chemotherapy O
started O
, O
patients O
were O
randomized O
to O
stress O
management O
training O
( O
SM O
) O
, O
exercise O
( O
EX O
) O
, O
combined O
stress O
management O
and O
exercise O
( O
SMEX O
) O
, O
or O
usual O
care O
only O
( O
UCO O
) O
. O

This O
phase O
III O
trial O
was O
conducted O
to O
test O
whether O
the O
novel O
vascular O
disrupting O
agent O
ASA404 O
( O
vadimezan O
) O
, O
when O
combined O
with O
first-line O
platinum-based O
chemotherapy O
, O
improves O
survival O
in O
patients O
with O
advanced O
non-small-cell O
lung O
cancer O
( O
NSCLC O
) O
versus O
chemotherapy O
alone O
. O

A O
regression O
analysis O
with O
interactions O
was O
performed O
to O
determine O
if O
domains O
of O
quality O
of O
life O
( O
EORTC-QLQ-C30 O
) O
functioning O
( O
Health O
Survey O
Short O
Form-36 O
) O
or O
psychological O
distress O
( O
Symptom O
Checklist-90 O
) O
moderated O
the O
effect O
of O
CBT O
on O
fatigue O
. O

Patients O
received O
either O
r-HuEPO O
( O
150 O
U/kg O
) O
or O
placebo O
, O
subcutaneously O
, O
three O
times O
a O
week O
for O
3 O
months O
. O

The O
impact O
of O
psychotherapeutic O
support O
on O
survival O
for O
patients O
with O
gastrointestinal O
cancer O
undergoing O
surgery O
was O
studied O
. O

CBR B-Premise
was I-Premise
45.6 I-Premise
% I-Premise
for I-Premise
fulvestrant I-Premise
500 I-Premise
mg I-Premise
and I-Premise
39.6 I-Premise
% I-Premise
for I-Premise
fulvestrant I-Premise
250 I-Premise
mg. I-Premise
DoCB B-Premise
and I-Premise
OS I-Premise
were I-Premise
16.6 I-Premise
and I-Premise
25.1 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
, I-Premise
for I-Premise
the I-Premise
500-mg I-Premise
group I-Premise
, I-Premise
whereas I-Premise
DoCB I-Premise
and I-Premise
OS I-Premise
were I-Premise
13.9 I-Premise
and I-Premise
22.8 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
, I-Premise
in I-Premise
the I-Premise
250-mg I-Premise
group I-Premise
. I-Premise

We O
recruited O
273 O
participants O
and O
randomly O
assigned O
136 O
to O
the O
intervention O
group O
. O

When B-Premise
stent I-Premise
obstruction I-Premise
was I-Premise
not I-Premise
regarded I-Premise
as I-Premise
a I-Premise
major I-Premise
complication I-Premise
, I-Premise
no I-Premise
differences I-Premise
in I-Premise
complications I-Premise
were I-Premise
found I-Premise
( I-Premise
P I-Premise
= I-Premise
.4 I-Premise
) I-Premise
. I-Premise

Global B-Premise
QOL I-Premise
, I-Premise
emotional/role I-Premise
functioning I-Premise
, I-Premise
nausea/vomiting I-Premise
, I-Premise
pain I-Premise
, I-Premise
swallowing I-Premise
, I-Premise
speech I-Premise
, I-Premise
social I-Premise
contact/eating I-Premise
, I-Premise
insomnia I-Premise
showed I-Premise
rapid I-Premise
recovery I-Premise
( I-Premise
< I-Premise
6months I-Premise
) I-Premise
while I-Premise
physical/cognitive I-Premise
functioning I-Premise
, I-Premise
dry I-Premise
mouth I-Premise
, I-Premise
sticky I-Premise
saliva I-Premise
, I-Premise
fatigue I-Premise
, I-Premise
senses I-Premise
showed I-Premise
delayed I-Premise
recovery I-Premise
( I-Premise
> I-Premise
6months I-Premise
) I-Premise
. I-Premise

Hormone B-Claim
replacement I-Claim
therapy I-Claim
is I-Claim
often I-Claim
either I-Claim
undesirable I-Claim
or I-Claim
contraindicated I-Claim
. I-Claim

Bone B-Claim
metastases I-Claim
are I-Claim
a I-Claim
common I-Claim
cause I-Claim
of I-Claim
morbidity I-Claim
in I-Claim
patients I-Claim
with I-Claim
prostate I-Claim
carcinoma I-Claim
. I-Claim

Impaired B-Claim
cognition I-Claim
, I-Claim
fatigue I-Claim
, I-Claim
and I-Claim
diminished I-Claim
quality I-Claim
of I-Claim
life I-Claim
( I-Claim
QOL I-Claim
) I-Claim
are I-Claim
commonly I-Claim
associated I-Claim
with I-Claim
breast I-Claim
cancer I-Claim
chemotherapy I-Claim
. I-Claim

The B-Claim
analgesic I-Claim
effects I-Claim
of I-Claim
amitriptyline I-Claim
were I-Claim
slight I-Claim
and I-Claim
associated I-Claim
with I-Claim
adverse I-Claim
effects I-Claim
. I-Claim

The B-Claim
generalizability I-Claim
of I-Claim
palliative I-Claim
care I-Claim
intervention I-Claim
research I-Claim
is I-Claim
often I-Claim
limited I-Claim
by I-Claim
high I-Claim
rates I-Claim
of I-Claim
study I-Claim
attrition I-Claim
. I-Claim

For B-Premise
sexually I-Premise
active I-Premise
female I-Premise
rectal I-Premise
and I-Premise
anal I-Premise
cancer I-Premise
survivors I-Premise
enrolled I-Premise
in I-Premise
a I-Premise
sexual I-Premise
health I-Premise
intervention I-Premise
, I-Premise
sexual I-Premise
dysfunction I-Premise
was I-Premise
significantly I-Premise
and I-Premise
consistently I-Premise
associated I-Premise
with I-Premise
specific I-Premise
measures I-Premise
of I-Premise
psychological I-Premise
well-being I-Premise
, I-Premise
most I-Premise
notably I-Premise
Sexual/Relationship I-Premise
Satisfaction I-Premise
. I-Premise

Erlotinib B-Claim
was I-Claim
effective I-Claim
and I-Claim
well I-Claim
tolerated I-Claim
in I-Claim
Asian I-Claim
patients I-Claim
, I-Claim
producing I-Claim
benefits I-Claim
consistent I-Claim
with I-Claim
those I-Claim
observed I-Claim
in I-Claim
the I-Claim
overall I-Claim
SATURN I-Claim
population I-Claim
. I-Claim

Additionally B-Premise
, I-Premise
patients I-Premise
started I-Premise
on I-Premise
strong I-Premise
opioids I-Premise
required I-Premise
significantly I-Premise
fewer I-Premise
changes I-Premise
in I-Premise
therapy I-Premise
, I-Premise
had I-Premise
greater I-Premise
reduction I-Premise
in I-Premise
pain I-Premise
when I-Premise
a I-Premise
change I-Premise
was I-Premise
initiated I-Premise
, I-Premise
and I-Premise
reported I-Premise
greater I-Premise
satisfaction I-Premise
with I-Premise
treatment I-Premise
than I-Premise
the I-Premise
comparator I-Premise
group I-Premise
( I-Premise
P=0.041 I-Premise
) I-Premise
. I-Premise

Need B-Premise
for I-Premise
reintervention I-Premise
was I-Premise
19 I-Premise
, I-Premise
10 I-Premise
, I-Premise
and I-Premise
33 I-Premise
% I-Premise
in I-Premise
these I-Premise
groups I-Premise
, I-Premise
respectively I-Premise
( I-Premise
p I-Premise
= I-Premise
0.123 I-Premise
) I-Premise
. I-Premise

The B-Premise
acceptance I-Premise
of I-Premise
K-tape I-Premise
was I-Premise
better I-Premise
than I-Premise
the I-Premise
bandage I-Premise
, I-Premise
and I-Premise
benefits I-Premise
included I-Premise
longer I-Premise
wearing I-Premise
time I-Premise
, I-Premise
less I-Premise
difficulty I-Premise
in I-Premise
usage I-Premise
, I-Premise
and I-Premise
increased I-Premise
comfort I-Premise
and I-Premise
convenience I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Based B-Premise
on I-Premise
the I-Premise
results I-Premise
of I-Premise
the I-Premise
area I-Premise
under I-Premise
the I-Premise
curve I-Premise
( I-Premise
AUC I-Premise
) I-Premise
analysis I-Premise
, I-Premise
patients I-Premise
receiving I-Premise
HMB/Arg/Gln I-Premise
had I-Premise
a I-Premise
strong I-Premise
trend I-Premise
higher I-Premise
LBM I-Premise
throughout I-Premise
the I-Premise
study I-Premise
as I-Premise
measured I-Premise
by I-Premise
both I-Premise
bioimpedance I-Premise
( I-Premise
p I-Premise
= I-Premise
0.08 I-Premise
) I-Premise
and I-Premise
skin-fold I-Premise
measurements I-Premise
( I-Premise
p I-Premise
= I-Premise
0.08 I-Premise
) I-Premise
. I-Premise

GHS B-Premise
change I-Premise
scores I-Premise
were I-Premise
-0.5 I-Premise
and I-Premise
-7.1 I-Premise
( I-Premise
P I-Premise
= I-Premise
.008 I-Premise
) I-Premise
at I-Premise
8 I-Premise
weeks I-Premise
and I-Premise
were I-Premise
-3.6 I-Premise
and I-Premise
-15.2 I-Premise
( I-Premise
P I-Premise
= I-Premise
.008 I-Premise
) I-Premise
at I-Premise
16 I-Premise
weeks I-Premise
for I-Premise
cetuximab I-Premise
and I-Premise
BSC I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Results B-Premise
from I-Premise
the I-Premise
non-randomised I-Premise
patients I-Premise
did I-Premise
not I-Premise
confirm I-Premise
this I-Premise
effect I-Premise
, I-Premise
however I-Premise
. I-Premise

Opioid B-Premise
escalation I-Premise
index I-Premise
was I-Premise
significantly I-Premise
lower I-Premise
in I-Premise
patients I-Premise
receiving I-Premise
methadone I-Premise
( I-Premise
p I-Premise
< I-Premise
0.0001 I-Premise
) I-Premise
, I-Premise
although I-Premise
requiring I-Premise
up I-Premise
and I-Premise
down I-Premise
changes I-Premise
in I-Premise
doses I-Premise
. I-Premise

CP B-Premise
resulted I-Premise
in I-Premise
more I-Premise
anastomotic I-Premise
leaks I-Premise
. I-Premise

Eight B-Premise
of I-Premise
the I-Premise
17 I-Premise
quality-of-life I-Premise
( I-Premise
QOL I-Premise
) I-Premise
variables I-Premise
assessed I-Premise
showed I-Premise
an I-Premise
improvement I-Premise
of I-Premise
more I-Premise
than I-Premise
10 I-Premise
% I-Premise
between I-Premise
baseline I-Premise
and I-Premise
the I-Premise
start I-Premise
of I-Premise
the I-Premise
third I-Premise
cycle I-Premise
of I-Premise
treatment I-Premise
. I-Premise

There B-Premise
was I-Premise
significantly I-Premise
more I-Premise
grade I-Premise
3-4 I-Premise
neutropenia I-Premise
( I-Premise
P I-Premise
= I-Premise
.001 I-Premise
) I-Premise
and I-Premise
dyspnea I-Premise
( I-Premise
P I-Premise
= I-Premise
.014 I-Premise
) I-Premise
with I-Premise
PB+G I-Premise
. I-Premise

A B-Claim
three-times-per-week I-Claim
dosing I-Claim
schedule I-Claim
was I-Claim
noted I-Claim
to I-Claim
be I-Claim
more I-Claim
effective I-Claim
compared I-Claim
with I-Claim
a I-Claim
once-a-week I-Claim
schedule I-Claim
without I-Claim
any I-Claim
significant I-Claim
difference I-Claim
in I-Claim
toxicity I-Claim
reported I-Claim
. I-Claim

Gefitinib B-Claim
failed I-Claim
to I-Claim
demonstrate I-Claim
superior I-Claim
OS I-Claim
compared I-Claim
with I-Claim
GP I-Claim
as I-Claim
first-line I-Claim
therapy I-Claim
for I-Claim
NSLAs I-Claim
. I-Claim

The B-Claim
addition I-Claim
of I-Claim
gemcitabine I-Claim
to I-Claim
PB I-Claim
was I-Claim
not I-Claim
associated I-Claim
with I-Claim
a I-Claim
statistically I-Claim
significant I-Claim
improvement I-Claim
in I-Claim
ORR I-Claim
. I-Claim

AM B-Premise
was I-Premise
associated I-Premise
with I-Premise
higher I-Premise
rates I-Premise
of I-Premise
acute I-Premise
nausea I-Premise
( I-Premise
P I-Premise
= I-Premise
.03 I-Premise
) I-Premise
, I-Premise
vomiting I-Premise
( I-Premise
P I-Premise
= I-Premise
.007 I-Premise
) I-Premise
, I-Premise
cardiovascular I-Premise
toxicity I-Premise
( I-Premise
P I-Premise
= I-Premise
.0001 I-Premise
) I-Premise
, I-Premise
and I-Premise
infection I-Premise
or I-Premise
febrile I-Premise
neutropenia I-Premise
( I-Premise
P I-Premise
= I-Premise
.03 I-Premise
) I-Premise
. I-Premise

Time B-Premise
to I-Premise
final I-Premise
healing I-Premise
was I-Premise
significantly I-Premise
shorter I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
scores I-Premise
on I-Premise
the I-Premise
CWIS I-Premise
were I-Premise
higher I-Premise
in I-Premise
patients I-Premise
receiving I-Premise
RELP I-Premise
than I-Premise
in I-Premise
those I-Premise
receiving I-Premise
UM I-Premise
. I-Premise

The B-Premise
final I-Premise
multivariate I-Premise
model I-Premise
predicted I-Premise
poor I-Premise
survival I-Premise
with I-Premise
multiple I-Premise
sites I-Premise
of I-Premise
visceral I-Premise
disease I-Premise
( I-Premise
P=0.003 I-Premise
) I-Premise
, I-Premise
DFI I-Premise
< I-Premise
/=2 I-Premise
years I-Premise
( I-Premise
P=0.026 I-Premise
) I-Premise
and I-Premise
pain I-Premise
( I-Premise
P=0.003 I-Premise
) I-Premise
. I-Premise

Adjusted B-Premise
for I-Premise
baseline I-Premise
score I-Premise
, I-Premise
disease I-Premise
, I-Premise
and I-Premise
demographic I-Premise
covariates I-Premise
, I-Premise
the I-Premise
intervention I-Premise
group I-Premise
showed I-Premise
an I-Premise
estimated I-Premise
improvement I-Premise
at I-Premise
six I-Premise
weeks I-Premise
for I-Premise
the I-Premise
primary I-Premise
outcome I-Premise
, I-Premise
fatigue I-Premise
, I-Premise
of I-Premise
-6.6 I-Premise
points I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
-12.3 I-Premise
to I-Premise
-0.9 I-Premise
, I-Premise
P=0.02 I-Premise
";" I-Premise
effect I-Premise
size=0.33 I-Premise
, I-Premise
0.04 I-Premise
to I-Premise
0.61 I-Premise
) I-Premise
. I-Premise

Moreover O
, O
a B-Premise
significant I-Premise
lower I-Premise
serum I-Premise
C-reactive I-Premise
protein I-Premise
level I-Premise
was I-Premise
detected I-Premise
in I-Premise
glutamine-enriched I-Premise
TPN I-Premise
compared I-Premise
with I-Premise
standard I-Premise
TPN I-Premise
( I-Premise
P I-Premise
= I-Premise
0.013 I-Premise
) I-Premise
. I-Premise

Intensive B-Claim
nutrition I-Claim
intervention I-Claim
following I-Claim
the I-Claim
ADA I-Claim
MNT I-Claim
protocol I-Claim
results I-Claim
in I-Claim
improved I-Claim
dietary I-Claim
intake I-Claim
compared I-Claim
with I-Claim
standard I-Claim
practice I-Claim
and I-Claim
seems I-Claim
to I-Claim
beneficially I-Claim
impact I-Claim
nutrition-related I-Claim
outcomes I-Claim
previously I-Claim
observed I-Claim
in I-Claim
oncology I-Claim
outpatients I-Claim
receiving I-Claim
radiotherapy I-Claim
. I-Claim

By B-Premise
contrast I-Premise
, I-Premise
for I-Premise
patients I-Premise
with I-Premise
ER-positive I-Premise
tumors I-Premise
, I-Premise
addition I-Premise
of I-Premise
CMF I-Premise
provided I-Premise
no I-Premise
benefit I-Premise
in I-Premise
terms I-Premise
of I-Premise
DFS I-Premise
( I-Premise
5-year I-Premise
DFS I-Premise
= I-Premise
84 I-Premise
% I-Premise
for I-Premise
CMF I-Premise
-- I-Premise
> I-Premise
tamoxifen I-Premise
versus I-Premise
85 I-Premise
% I-Premise
for I-Premise
tamoxifen I-Premise
alone I-Premise
";" I-Premise
difference I-Premise
= I-Premise
-1 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
-6 I-Premise
% I-Premise
to I-Premise
4 I-Premise
% I-Premise
";" I-Premise
RR I-Premise
= I-Premise
0.99 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0.75 I-Premise
to I-Premise
1.30 I-Premise
";" I-Premise
P I-Premise
=.92 I-Premise
) I-Premise
or I-Premise
OS I-Premise
( I-Premise
5-year I-Premise
OS I-Premise
= I-Premise
95 I-Premise
% I-Premise
for I-Premise
CMF I-Premise
-- I-Premise
> I-Premise
tamoxifen I-Premise
versus I-Premise
93 I-Premise
% I-Premise
for I-Premise
tamoxifen I-Premise
alone I-Premise
";" I-Premise
difference I-Premise
= I-Premise
2 I-Premise
% I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
-1 I-Premise
% I-Premise
to I-Premise
5 I-Premise
% I-Premise
";" I-Premise
RR I-Premise
= I-Premise
0.95 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0.64 I-Premise
to I-Premise
1.40 I-Premise
";" I-Premise
P I-Premise
=.80 I-Premise
) I-Premise
. I-Premise

Fat-free B-Premise
mass I-Premise
showed I-Premise
an I-Premise
intergroup I-Premise
difference I-Premise
in I-Premise
favor I-Premise
of I-Premise
group I-Premise
B I-Premise
after I-Premise
eight I-Premise
weeks I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Mean B-Premise
hemoglobin I-Premise
levels I-Premise
were I-Premise
higher I-Premise
in I-Premise
the I-Premise
epoetin I-Premise
alfa I-Premise
group I-Premise
compared I-Premise
with I-Premise
the I-Premise
placebo I-Premise
group I-Premise
after I-Premise
4 I-Premise
cycles I-Premise
of I-Premise
chemotherapy I-Premise
. I-Premise

Supervised B-Claim
group I-Claim
exercise I-Claim
provided I-Claim
functional I-Claim
and I-Claim
psychological I-Claim
benefit I-Claim
after I-Claim
a I-Claim
12 I-Claim
week I-Claim
intervention I-Claim
and I-Claim
six I-Claim
months I-Claim
later I-Claim
. I-Claim

The B-Premise
treatments I-Premise
gave I-Premise
rise I-Premise
to I-Premise
different I-Premise
rates I-Premise
of I-Premise
grade I-Premise
3-4 I-Premise
neutropenia I-Premise
( I-Premise
3 I-Premise
, I-Premise
4 I-Premise
, I-Premise
11 I-Premise
and I-Premise
14 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
in I-Premise
the I-Premise
LV5FU2 I-Premise
, I-Premise
ldLV5FU2 I-Premise
, I-Premise
HD-FU I-Premise
and I-Premise
Tomudex I-Premise
arms I-Premise
, I-Premise
respectively I-Premise
, I-Premise
p I-Premise
= I-Premise
0.028 I-Premise
) I-Premise
, I-Premise
leucopenia I-Premise
and I-Premise
vomiting I-Premise
. I-Premise

The B-Premise
trial I-Premise
was I-Premise
stopped I-Premise
early I-Premise
because I-Premise
of I-Premise
poor I-Premise
accrual I-Premise
before I-Premise
the I-Premise
target I-Premise
of I-Premise
123 I-Premise
evaluable I-Premise
patients I-Premise
was I-Premise
met I-Premise
. I-Premise

This B-Claim
toxicity I-Claim
profile I-Claim
of I-Claim
GE I-Claim
is I-Claim
similar I-Claim
to I-Claim
GP I-Claim
, I-Claim
but B-Claim
the I-Claim
apparent I-Claim
inferior I-Claim
efficacy I-Claim
may I-Claim
discourage I-Claim
further I-Claim
investigation I-Claim
. O

No B-Claim
significant I-Claim
differences I-Claim
in I-Claim
terms I-Claim
of I-Claim
response I-Claim
rate I-Claim
, I-Claim
time I-Claim
to I-Claim
progression I-Claim
and I-Claim
overall I-Claim
survival I-Claim
were I-Claim
observed I-Claim
between I-Claim
the I-Claim
two I-Claim
regimen I-Claim
. I-Claim

In B-Premise
patients I-Premise
with I-Premise
low I-Premise
TS I-Premise
, I-Premise
no I-Premise
remarkable I-Premise
difference I-Premise
in I-Premise
overall I-Premise
response I-Premise
to I-Premise
FOLFIRI I-Premise
and I-Premise
FUFA I-Premise
was I-Premise
observed I-Premise
. I-Premise

Physical B-Premise
performance I-Premise
of I-Premise
the I-Premise
training I-Premise
group I-Premise
improved I-Premise
significantly I-Premise
during I-Premise
the I-Premise
programme I-Premise
( I-Premise
9.4+/-20 I-Premise
watts I-Premise
, I-Premise
p=0.01 I-Premise
) I-Premise
but I-Premise
remained I-Premise
unchanged I-Premise
in I-Premise
the I-Premise
relaxation I-Premise
group I-Premise
( I-Premise
1.5+/-14.8 I-Premise
watts I-Premise
, I-Premise
p=0.37 I-Premise
) I-Premise
. I-Premise

By B-Premise
the I-Premise
end I-Premise
of I-Premise
the I-Premise
treatment I-Premise
period I-Premise
, I-Premise
hot I-Premise
flash I-Premise
scores I-Premise
( I-Premise
frequency I-Premise
x I-Premise
average I-Premise
severity I-Premise
) I-Premise
decreased I-Premise
68 I-Premise
% I-Premise
from I-Premise
baseline I-Premise
to I-Premise
end I-Premise
point I-Premise
in I-Premise
the I-Premise
hypnosis I-Premise
arm I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

These B-Claim
data I-Claim
demonstrated I-Claim
a I-Claim
significant I-Claim
4.5-month I-Claim
median I-Claim
OS I-Claim
advantage I-Claim
with I-Claim
the I-Claim
lapatinib I-Claim
and I-Claim
trastuzumab I-Claim
combination I-Claim
and I-Claim
support I-Claim
dual I-Claim
HER2 I-Claim
blockade I-Claim
in I-Claim
patients I-Claim
with I-Claim
heavily I-Claim
pretreated I-Claim
HER2-positive I-Claim
MBC I-Claim
. I-Claim

Erlotinib B-Claim
not I-Claim
only I-Claim
improves I-Claim
survival I-Claim
in I-Claim
previously I-Claim
treated I-Claim
patients I-Claim
with I-Claim
NSCLC I-Claim
, I-Claim
but I-Claim
also I-Claim
improves I-Claim
tumor-related I-Claim
symptoms I-Claim
and I-Claim
important I-Claim
aspects I-Claim
of I-Claim
QOL I-Claim
. I-Claim

At B-Premise
least I-Premise
one I-Premise
episode I-Premise
of I-Premise
grade I-Premise
3-4 I-Premise
toxicity I-Premise
was I-Premise
observed I-Premise
in I-Premise
27 I-Premise
, I-Premise
25 I-Premise
, I-Premise
38 I-Premise
and I-Premise
47 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
in I-Premise
the I-Premise
LV5FU2 I-Premise
, I-Premise
ldLV5FU2 I-Premise
, I-Premise
HD-FU I-Premise
and I-Premise
Tomudex I-Premise
arms I-Premise
, I-Premise
respectively I-Premise
( I-Premise
p I-Premise
= I-Premise
0.016 I-Premise
) I-Premise
. I-Premise

Best B-Premise
response I-Premise
to I-Premise
induction I-Premise
therapy I-Premise
was I-Premise
complete I-Premise
remission I-Premise
for I-Premise
176 I-Premise
patients I-Premise
( I-Premise
33 I-Premise
% I-Premise
) I-Premise
, I-Premise
partial I-Premise
remission I-Premise
for I-Premise
341 I-Premise
( I-Premise
64 I-Premise
% I-Premise
) I-Premise
, I-Premise
and I-Premise
15 I-Premise
patients I-Premise
( I-Premise
3 I-Premise
% I-Premise
) I-Premise
had I-Premise
undergone I-Premise
surgical I-Premise
resection I-Premise
. I-Premise

The B-Claim
oral I-Claim
regimen I-Claim
also I-Claim
can I-Claim
be I-Claim
safely I-Claim
given I-Claim
with I-Claim
appropriate I-Claim
toxicity I-Claim
and I-Claim
tolerability I-Claim
. I-Claim

The B-Claim
implication I-Claim
is I-Claim
that I-Claim
CBT I-Claim
for I-Claim
fatigue I-Claim
should I-Claim
be I-Claim
offered I-Claim
to I-Claim
patients I-Claim
with I-Claim
cancer I-Claim
with I-Claim
the I-Claim
highest I-Claim
chance I-Claim
to I-Claim
benefit I-Claim
. I-Claim

Improvement B-Premise
over I-Premise
time I-Premise
and I-Premise
time I-Premise
x I-Premise
treatment I-Premise
effects I-Premise
only I-Premise
reached I-Premise
trend I-Premise
significance I-Premise
levels I-Premise
( I-Premise
ps I-Premise
= I-Premise
0.07 I-Premise
& I-Premise
amp I-Premise
";" I-Premise
0.12 I-Premise
) I-Premise
as I-Premise
this I-Premise
pilot I-Premise
was I-Premise
not I-Premise
powered I-Premise
to I-Premise
detect I-Premise
these I-Premise
differences I-Premise
. I-Premise

There B-Premise
was I-Premise
a I-Premise
trend I-Premise
towards I-Premise
an I-Premise
increase I-Premise
in I-Premise
OS I-Premise
, I-Premise
which I-Premise
reached I-Premise
statistical I-Premise
significance I-Premise
in I-Premise
the I-Premise
EGFR I-Premise
IHC-positive I-Premise
subgroup I-Premise
( I-Premise
p=0.0233 I-Premise
) I-Premise
. I-Premise

Women B-Claim
with I-Claim
breast I-Claim
cancer I-Claim
may I-Claim
have I-Claim
an I-Claim
even I-Claim
higher I-Claim
risk I-Claim
of I-Claim
depression I-Claim
particularly I-Claim
in I-Claim
a I-Claim
postmenopausal I-Claim
or I-Claim
estrogen I-Claim
deficiency I-Claim
state I-Claim
. I-Claim

No B-Premise
unexpected I-Premise
adverse I-Premise
events I-Premise
were I-Premise
observed I-Premise
, I-Premise
except B-Premise
for I-Premise
tumor I-Premise
hemorrhage-type I-Premise
events I-Premise
with I-Premise
gefitinib I-Premise
( I-Premise
8.9 I-Premise
% I-Premise
, I-Premise
gefitinib I-Premise
250 I-Premise
mg/day I-Premise
";" I-Premise
11.4 I-Premise
% I-Premise
, I-Premise
gefitinib I-Premise
500 I-Premise
mg/day I-Premise
";" I-Premise
1.9 I-Premise
% I-Premise
, I-Premise
methotrexate I-Premise
) I-Premise
. I-Premise

ORR B-Premise
was I-Premise
25.0 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
13 I-Premise
% I-Premise
to I-Premise
41 I-Premise
% I-Premise
) I-Premise
for I-Premise
ECF I-Premise
, I-Premise
18.5 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
9 I-Premise
% I-Premise
to I-Premise
34 I-Premise
% I-Premise
) I-Premise
for I-Premise
TC I-Premise
, I-Premise
and I-Premise
36.6 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
23 I-Premise
% I-Premise
to I-Premise
53 I-Premise
% I-Premise
) I-Premise
for I-Premise
TCF I-Premise
( I-Premise
n I-Premise
= I-Premise
119 I-Premise
) I-Premise
. I-Premise

Erlotinib B-Claim
was I-Claim
superior I-Claim
to I-Claim
placebo I-Claim
for I-Claim
survival I-Claim
, I-Claim
progression-free I-Claim
survival I-Claim
, I-Claim
and I-Claim
tumor I-Claim
response I-Claim
rate I-Claim
. I-Claim

The B-Claim
effects I-Claim
of I-Claim
Pemetrexed I-Claim
and I-Claim
Gefitinib I-Claim
as I-Claim
second I-Claim
line I-Claim
therapy I-Claim
were I-Claim
similar I-Claim
, I-Claim
although B-Premise
with I-Premise
different I-Premise
AEs I-Premise
. I-Premise

From B-Premise
3 I-Premise
to I-Premise
9 I-Premise
months I-Premise
, I-Premise
changes I-Premise
of I-Premise
QoL I-Premise
scales I-Premise
and I-Premise
subscales I-Premise
were I-Premise
no I-Premise
longer I-Premise
statistically I-Premise
different I-Premise
in I-Premise
both I-Premise
groups I-Premise
of I-Premise
patients I-Premise
. I-Premise

Elbow B-Premise
flexor I-Premise
muscle I-Premise
strength I-Premise
declined I-Premise
by I-Premise
-5.5 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
-9.6 I-Premise
% I-Premise
to I-Premise
-1 I-Premise
. I-Premise
4 I-Premise
% I-Premise
) I-Premise
per I-Premise
4 I-Premise
weeks I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
but I-Premise
remained I-Premise
stable I-Premise
( I-Premise
0.0 I-Premise
% I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI= I-Premise
-1.4 I-Premise
% I-Premise
to I-Premise
+1.4 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
ATP I-Premise
group I-Premise
( I-Premise
P I-Premise
=.01 I-Premise
) I-Premise
. I-Premise

Two B-Premise
patients I-Premise
treated I-Premise
with I-Premise
a I-Premise
cumulative I-Premise
dose I-Premise
of I-Premise
MMC I-Premise
of I-Premise
40 I-Premise
mg/m2 I-Premise
developed I-Premise
haemolytic I-Premise
uraemic I-Premise
syndrome I-Premise
warranting I-Premise
the I-Premise
reduction I-Premise
in I-Premise
cumulative I-Premise
MMC I-Premise
dose I-Premise
to I-Premise
28 I-Premise
mg/m2 I-Premise
. I-Premise

Sertraline B-Premise
had I-Premise
no I-Premise
significant I-Premise
effect I-Premise
( I-Premise
scale I-Premise
, I-Premise
benefit I-Premise
over I-Premise
placebo I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
] I-Premise
) I-Premise
on I-Premise
depression I-Premise
( I-Premise
CES-D I-Premise
0.4 I-Premise
[ I-Premise
-2.6 I-Premise
to I-Premise
3.4 I-Premise
] I-Premise
) I-Premise
, I-Premise
anxiety I-Premise
( I-Premise
HADS-A I-Premise
2.0 I-Premise
[ I-Premise
-1.5 I-Premise
to I-Premise
5.5 I-Premise
] I-Premise
) I-Premise
, I-Premise
fatigue I-Premise
( I-Premise
FACT-F I-Premise
0.3 I-Premise
[ I-Premise
-4.3 I-Premise
to I-Premise
4.9 I-Premise
] I-Premise
) I-Premise
, I-Premise
overall I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
FACT-G I-Premise
1.7 I-Premise
[ I-Premise
-1.3 I-Premise
to I-Premise
4.7 I-Premise
] I-Premise
) I-Premise
, I-Premise
or I-Premise
clinicians I-Premise
' I-Premise
ratings I-Premise
( I-Premise
SQLI I-Premise
2.0 I-Premise
[ I-Premise
-2.5 I-Premise
to I-Premise
6.5 I-Premise
] I-Premise
) I-Premise
, I-Premise
and I-Premise
the I-Premise
95 I-Premise
% I-Premise
CI I-Premise
ruled I-Premise
out I-Premise
a I-Premise
clinically I-Premise
significant I-Premise
benefit I-Premise
for I-Premise
all I-Premise
main I-Premise
outcomes I-Premise
. I-Premise

The B-Claim
hypothesis I-Claim
of I-Claim
a I-Claim
RR I-Claim
15 I-Claim
% I-Claim
higher I-Claim
than I-Claim
the I-Claim
MTX I-Claim
+ I-Claim
LFA-5-FU I-Claim
treatment I-Claim
can I-Claim
not I-Claim
be I-Claim
ruled I-Claim
out I-Claim
after I-Claim
this I-Claim
interim I-Claim
analysis I-Claim
. I-Claim

No B-Claim
differences I-Claim
in I-Claim
patients I-Claim
' I-Claim
appetite I-Claim
or I-Claim
QOL I-Claim
were I-Claim
found I-Claim
either I-Claim
between I-Claim
CE I-Claim
, I-Claim
THC I-Claim
, I-Claim
and I-Claim
PL I-Claim
or I-Claim
between I-Claim
CE I-Claim
and I-Claim
THC I-Claim
at I-Claim
the I-Claim
dosages I-Claim
investigated I-Claim
. I-Claim

The B-Claim
effect I-Claim
appeared I-Claim
to I-Claim
be I-Claim
dose-dependent I-Claim
. I-Claim

Additional B-Claim
studies I-Claim
are I-Claim
warranted I-Claim
. I-Claim

Both B-Claim
the I-Claim
III I-Claim
+ I-Claim
ISG I-Claim
and I-Claim
III-only I-Claim
demonstrated I-Claim
pre-post I-Claim
reductions I-Claim
in I-Claim
depressive I-Claim
symptoms I-Claim
and I-Claim
high I-Claim
rates I-Claim
of I-Claim
utilization I-Claim
compared I-Claim
with I-Claim
other I-Claim
web-based I-Claim
treatments I-Claim
for I-Claim
depression I-Claim
. I-Claim

Patients B-Claim
who I-Claim
underwent I-Claim
gastric I-Claim
tube I-Claim
reconstruction I-Claim
develop I-Claim
less I-Claim
postoperative I-Claim
digestive I-Claim
tract I-Claim
complications I-Claim
, I-Claim
and I-Claim
have I-Claim
a I-Claim
quicker I-Claim
recovery I-Claim
and I-Claim
a I-Claim
better I-Claim
QoL I-Claim
during I-Claim
the I-Claim
follow-up I-Claim
period I-Claim
. I-Claim

Clinically B-Claim
, I-Claim
HBO I-Claim
appears I-Claim
to I-Claim
be I-Claim
a I-Claim
useful I-Claim
adjunct I-Claim
to I-Claim
ONJ I-Claim
treatment I-Claim
, I-Claim
particularly I-Claim
for I-Claim
more I-Claim
severe I-Claim
cases I-Claim
, I-Claim
although I-Claim
this I-Claim
study I-Claim
was I-Claim
underpowered I-Claim
to I-Claim
fully I-Claim
support I-Claim
this I-Claim
claim I-Claim
. I-Claim

The B-Claim
sequential I-Claim
addition I-Claim
of I-Claim
topotecan I-Claim
to I-Claim
carboplatin-paclitaxel I-Claim
did I-Claim
not I-Claim
result I-Claim
in I-Claim
superior I-Claim
overall I-Claim
response I-Claim
or I-Claim
progression-free I-Claim
or I-Claim
overall I-Claim
survival I-Claim
. I-Claim

Patients B-Claim
who I-Claim
performed I-Claim
prophylactic I-Claim
swallowing I-Claim
exercises I-Claim
had I-Claim
improved I-Claim
swallowing I-Claim
function I-Claim
at I-Claim
3 I-Claim
and I-Claim
6 I-Claim
months I-Claim
after I-Claim
CRT I-Claim
but I-Claim
not I-Claim
immediately I-Claim
after I-Claim
CRT I-Claim
or I-Claim
at I-Claim
9 I-Claim
and I-Claim
12 I-Claim
months I-Claim
after I-Claim
CRT I-Claim
. I-Claim

The B-Claim
survival I-Claim
with I-Claim
DOX I-Claim
and I-Claim
VNB I-Claim
is I-Claim
not I-Claim
superior I-Claim
to I-Claim
DOX I-Claim
alone I-Claim
in I-Claim
MBC I-Claim
. I-Claim

Furthermore O
, O
if B-Claim
offered I-Claim
the I-Claim
choice I-Claim
, I-Claim
the I-Claim
majority I-Claim
of I-Claim
cancer I-Claim
survivors I-Claim
seem I-Claim
to I-Claim
prefer I-Claim
multidimensional I-Claim
programs I-Claim
to I-Claim
programs I-Claim
with I-Claim
only I-Claim
one I-Claim
component I-Claim
. I-Claim

Both B-Claim
drugs I-Claim
could I-Claim
improve I-Claim
the I-Claim
QoL I-Claim
, I-Claim
but O
Gefitinib B-Claim
showed I-Claim
better I-Claim
overall I-Claim
results I-Claim
than I-Claim
Pemetrexed I-Claim
. I-Claim

The B-Claim
efficacy I-Claim
and I-Claim
safety I-Claim
of I-Claim
uterine-artery I-Claim
embolization I-Claim
, I-Claim
as I-Claim
compared I-Claim
with I-Claim
standard I-Claim
surgical I-Claim
methods I-Claim
, I-Claim
for I-Claim
the I-Claim
treatment I-Claim
of I-Claim
symptomatic I-Claim
uterine I-Claim
fibroids I-Claim
remain I-Claim
uncertain I-Claim
. I-Claim

There B-Claim
were I-Claim
no I-Claim
unexpected I-Claim
hematological I-Claim
or I-Claim
non-hematological I-Claim
toxicities I-Claim
. I-Claim

Improvements B-Claim
in I-Claim
total I-Claim
quality-of-life I-Claim
change I-Claim
scores I-Claim
demonstrated I-Claim
that I-Claim
at I-Claim
6 I-Claim
months I-Claim
, I-Claim
improvements I-Claim
were I-Claim
more I-Claim
than I-Claim
twice I-Claim
as I-Claim
large I-Claim
and I-Claim
clinically I-Claim
significant I-Claim
in I-Claim
the I-Claim
intervention I-Claim
compared I-Claim
with I-Claim
the I-Claim
control I-Claim
group I-Claim
. I-Claim

Whether B-Claim
such I-Claim
a I-Claim
lozenge I-Claim
would I-Claim
be I-Claim
beneficial I-Claim
in I-Claim
treatment I-Claim
situations I-Claim
where I-Claim
rate I-Claim
of I-Claim
severe I-Claim
mucositis I-Claim
is I-Claim
higher I-Claim
( I-Claim
ie I-Claim
, I-Claim
in I-Claim
patients I-Claim
treated I-Claim
with I-Claim
unconventional I-Claim
fractionation I-Claim
or I-Claim
with I-Claim
concomitant I-Claim
chemotherapy I-Claim
) I-Claim
is I-Claim
unknown I-Claim
. I-Claim

The B-Claim
3-hour I-Claim
infusion I-Claim
of I-Claim
Taxol I-Claim
is I-Claim
safe I-Claim
when I-Claim
given I-Claim
with I-Claim
premedication I-Claim
and I-Claim
is I-Claim
associated I-Claim
with I-Claim
less I-Claim
neutropenia I-Claim
. I-Claim

Malignant B-Claim
pleural I-Claim
effusion I-Claim
( I-Claim
MPE I-Claim
) I-Claim
is I-Claim
a I-Claim
common I-Claim
complication I-Claim
of I-Claim
advanced I-Claim
non-small I-Claim
cell I-Claim
lung I-Claim
cancer I-Claim
( I-Claim
NSCLC I-Claim
) I-Claim
. I-Claim

After B-Claim
1 I-Claim
month I-Claim
of I-Claim
r-HuEPO I-Claim
, I-Claim
there I-Claim
is I-Claim
also I-Claim
a I-Claim
reduction I-Claim
in I-Claim
transfusion I-Claim
requirement I-Claim
. I-Claim

Doses B-Claim
to I-Claim
the I-Claim
IUS I-Claim
and I-Claim
EUS I-Claim
on I-Claim
MRI/CT I-Claim
predicted I-Claim
worse I-Claim
urinary I-Claim
function I-Claim
, I-Claim
with I-Claim
greater I-Claim
bother I-Claim
, I-Claim
irritative I-Claim
symptoms I-Claim
, I-Claim
and I-Claim
urgency I-Claim
. I-Claim

In B-Claim
conclusion I-Claim
, I-Claim
we I-Claim
were I-Claim
unable I-Claim
to I-Claim
identify I-Claim
a I-Claim
reduction I-Claim
in I-Claim
radiation-induced I-Claim
mucositis I-Claim
in I-Claim
patients I-Claim
receiving I-Claim
misoprostol I-Claim
. I-Claim

Medical B-Claim
castration I-Claim
reduces I-Claim
TPV I-Claim
and I-Claim
could I-Claim
also I-Claim
improve I-Claim
LUTS I-Claim
in I-Claim
patients I-Claim
with I-Claim
PCa I-Claim
. I-Claim

The B-Claim
study I-Claim
fails I-Claim
to I-Claim
demonstrate I-Claim
efficacy I-Claim
of I-Claim
dl-alpha I-Claim
tocopheryl I-Claim
acetate I-Claim
plus I-Claim
pentoxifylline I-Claim
in I-Claim
patients I-Claim
with I-Claim
arm I-Claim
lymphoedema I-Claim
following I-Claim
axillary I-Claim
surgery I-Claim
and I-Claim
lymphatic I-Claim
radiotherapy I-Claim
, I-Claim
nor I-Claim
does I-Claim
it I-Claim
suggest I-Claim
any I-Claim
benefits I-Claim
of I-Claim
these I-Claim
drugs I-Claim
in I-Claim
radiation-induced I-Claim
induration I-Claim
( I-Claim
fibrosis I-Claim
) I-Claim
in I-Claim
the I-Claim
breast I-Claim
, I-Claim
chest I-Claim
wall I-Claim
, I-Claim
pectoral I-Claim
fold I-Claim
, I-Claim
axilla I-Claim
or I-Claim
supraclavicular I-Claim
fossa I-Claim
. I-Claim

We B-Claim
can I-Claim
not I-Claim
exclude I-Claim
the I-Claim
possibility I-Claim
that I-Claim
a I-Claim
longer I-Claim
and I-Claim
more I-Claim
intense I-Claim
acupuncture I-Claim
intervention I-Claim
could I-Claim
produce I-Claim
a I-Claim
larger I-Claim
reduction I-Claim
of I-Claim
these I-Claim
symptoms I-Claim
. I-Claim

However B-Claim
, I-Claim
monitoring I-Claim
the I-Claim
lymphocyte I-Claim
count I-Claim
is I-Claim
advisable I-Claim
. I-Claim

Experimental B-Claim
surgery I-Claim
on I-Claim
pigs I-Claim
has I-Claim
suggested I-Claim
that I-Claim
a I-Claim
coloplasty I-Claim
pouch I-Claim
( I-Claim
CP I-Claim
) I-Claim
may I-Claim
be I-Claim
a I-Claim
useful I-Claim
alternative I-Claim
. O

However B-Claim
, I-Claim
it I-Claim
provided I-Claim
no I-Claim
improvement I-Claim
in I-Claim
PFS I-Claim
or I-Claim
OS I-Claim
compared I-Claim
with I-Claim
flat I-Claim
dosing I-Claim
. I-Claim

QOL B-Claim
was I-Claim
similar I-Claim
for I-Claim
both I-Claim
arms I-Claim
. I-Claim

The B-Claim
postoperative I-Claim
clinical I-Claim
superiority I-Claim
of I-Claim
the I-Claim
interposition I-Claim
of I-Claim
jejunum I-Claim
reconstruction I-Claim
( I-Claim
INT I-Claim
) I-Claim
to I-Claim
Roux-en-Y I-Claim
reconstruction I-Claim
( I-Claim
RY I-Claim
) I-Claim
after I-Claim
total I-Claim
gastrectomy I-Claim
has I-Claim
not I-Claim
been I-Claim
clarified I-Claim
. I-Claim

It B-Claim
seems I-Claim
to I-Claim
be I-Claim
safe I-Claim
, I-Claim
and I-Claim
its I-Claim
long-term I-Claim
effectiveness I-Claim
is I-Claim
worthy I-Claim
of I-Claim
further I-Claim
investigation I-Claim
. I-Claim

Therefore B-Claim
, I-Claim
pemetrexed I-Claim
combined I-Claim
with I-Claim
cisplatin I-Claim
can I-Claim
be I-Claim
used I-Claim
as I-Claim
a I-Claim
safe I-Claim
and I-Claim
effective I-Claim
drug I-Claim
for I-Claim
clinical I-Claim
first-line I-Claim
treatment I-Claim
for I-Claim
previously I-Claim
untreated I-Claim
NSCLC I-Claim
. I-Claim

Switching B-Claim
to I-Claim
anastrozole I-Claim
strongly I-Claim
decreased I-Claim
the I-Claim
endometrial I-Claim
thickness I-Claim
and I-Claim
uterine I-Claim
volume I-Claim
but I-Claim
increased I-Claim
sexual I-Claim
disturbances I-Claim
. I-Claim

More B-Claim
patients I-Claim
treated I-Claim
on I-Claim
4 I-Claim
consecutive I-Claim
days I-Claim
reported I-Claim
a I-Claim
clinically I-Claim
meaningful I-Claim
increase I-Claim
in I-Claim
dyspnea I-Claim
, I-Claim
although B-Claim
interpretation I-Claim
of I-Claim
these I-Claim
results I-Claim
is I-Claim
challenging I-Claim
due I-Claim
to I-Claim
baseline I-Claim
imbalance I-Claim
between I-Claim
treatment I-Claim
groups I-Claim
. I-Claim

Pilates B-Claim
exercises I-Claim
are I-Claim
effective I-Claim
and I-Claim
safe I-Claim
in I-Claim
female I-Claim
breast I-Claim
cancer I-Claim
patients I-Claim
. I-Claim

The B-Claim
effect I-Claim
of I-Claim
grape I-Claim
juice I-Claim
flavonoids I-Claim
on I-Claim
CINV I-Claim
should I-Claim
be I-Claim
investigated I-Claim
further I-Claim
with I-Claim
a I-Claim
larger I-Claim
sample I-Claim
to I-Claim
determine I-Claim
whether I-Claim
preliminary I-Claim
findings I-Claim
are I-Claim
supported I-Claim
. I-Claim

EGFR-mutated B-Claim
patients I-Claim
had I-Claim
better I-Claim
survival I-Claim
than I-Claim
those I-Claim
with I-Claim
EGFR I-Claim
wild-type I-Claim
disease I-Claim
, I-Claim
regardless I-Claim
of I-Claim
the I-Claim
treatment I-Claim
received I-Claim
. I-Claim

Data B-Claim
suggest I-Claim
that I-Claim
the I-Claim
GE I-Claim
combination I-Claim
may I-Claim
improve I-Claim
clinical I-Claim
outcomes I-Claim
. I-Claim

Exercise B-Claim
training I-Claim
to I-Claim
improve I-Claim
cardiovascular I-Claim
fitness I-Claim
should I-Claim
be I-Claim
considered I-Claim
in I-Claim
the I-Claim
management I-Claim
of I-Claim
lymphoma I-Claim
patients I-Claim
. I-Claim

Complete B-Claim
fibroid I-Claim
infarction I-Claim
does I-Claim
not I-Claim
translate I-Claim
into I-Claim
total I-Claim
freedom I-Claim
from I-Claim
a I-Claim
subsequent I-Claim
reintervention I-Claim
. I-Claim

Patients B-Claim
receiving I-Claim
concomitant I-Claim
and I-Claim
maintenance I-Claim
temozolomide I-Claim
+ I-Claim
radiotherapy I-Claim
had I-Claim
significantly I-Claim
improved I-Claim
overall I-Claim
survival I-Claim
. I-Claim

These B-Claim
interim I-Claim
data I-Claim
indicate I-Claim
no I-Claim
early I-Claim
evidence I-Claim
of I-Claim
detriment I-Claim
to I-Claim
quality I-Claim
of I-Claim
life I-Claim
, I-Claim
overall I-Claim
survival I-Claim
or I-Claim
QALYs I-Claim
for I-Claim
patients I-Claim
allocated I-Claim
to I-Claim
OSC I-Claim
alone I-Claim
. I-Claim

